579 lines
235 KiB
Text
579 lines
235 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548931">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548931/?report=reader">
|
|
<meta name="ncbi_pagename" content="Androgenic Steroids - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Androgenic Steroids - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Anastrozole/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/GeneralAnesthetics/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Androgenic Steroids">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2020/05/30">
|
|
<meta name="citation_pmid" content="31644236">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548931/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Androgenic Steroids">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2020/05/30">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548931/">
|
|
<meta name="description" content="Androgenic steroids are used for male sex hormone replacement and in the therapy of malignancies. The androgens also have anabolic effects and are used in catabolic or muscle wasting states. In addition, the synthetic anabolic steroids are now widely used illicitly for exercise and athletic performance enhancement. Many synthetic androgenic steroids are capable of causing cholestatic liver injury and long term use of androgens is associated with development of liver tumors including hepatocellular carcinoma, hepatic adenoma and vascular changes (peliosis hepatis).">
|
|
<meta name="og:title" content="Androgenic Steroids">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Androgenic steroids are used for male sex hormone replacement and in the therapy of malignancies. The androgens also have anabolic effects and are used in catabolic or muscle wasting states. In addition, the synthetic anabolic steroids are now widely used illicitly for exercise and athletic performance enhancement. Many synthetic androgenic steroids are capable of causing cholestatic liver injury and long term use of androgens is associated with development of liver tumors including hepatocellular carcinoma, hepatic adenoma and vascular changes (peliosis hepatis).">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548931/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/AndrogenicSteroids/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548931/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D05627D7B5A3100000000008B0076.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548931/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Anastrozole/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Androgenic Steroids</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/GeneralAnesthetics/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548931/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548931/&text=Androgenic%20Steroids"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548931/?report=classic">Switch to classic view</a><a href="/books/NBK548931/pdf/Bookshelf_NBK548931.pdf">PDF (402K)</a><a href="/books/NBK548931/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548931%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D05627D7B5A3100000000008B0076.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548931_"><span class="title" itemprop="name">Androgenic Steroids</span></h1><p class="fm-aai"><a href="#_NBK548931_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="AndrogenicSteroids.OVERVIEW"><h2 id="_AndrogenicSteroids_OVERVIEW_">OVERVIEW</h2><div id="AndrogenicSteroids.Introduction"><h3>Introduction</h3><p>Androgenic steroids are used for male sex hormone replacement and in the therapy of malignancies. The androgens also have anabolic effects and are used in catabolic or muscle wasting states. In addition, the synthetic anabolic steroids are now widely used illicitly for exercise and athletic performance enhancement. Many synthetic androgenic steroids are capable of causing cholestatic liver injury and long term use of androgens is associated with development of liver tumors including hepatocellular carcinoma, hepatic adenoma and vascular changes (peliosis hepatis).</p></div><div id="AndrogenicSteroids.Background"><h3>Background</h3><p>Testosterone is the major male sex hormone and is produced by the male testes in men and to a lesser extent by the adrenal glands in both men and women. Unmodified testosterone is not orally available, so it must be given intramuscularly, sublingually or by transcutaneous patch. Modifications of testosterone have been developed that are more bioavailable or have a longer duration of action. Modification by C-17β esterification (testosterone cypionate, enanthate and propionate) maintains the virilizing effects of testosterone, but increases potency and duration of action. Alkylation of the C-17α position of testosterone allows for oral administration by inhibiting metabolic deactivation in the liver and often alters the relative anabolic potency in relation to the masculinizing effects. The C-17 alkylated testosterones include methyltestosterone (meth" il tes tos' ter one), methandrostenolone (meth an" droe stene' oh lone), oxymetholone (ox" i meth' oh lone), danazol (dan' a zol), epistane (ep is tane’), fluoxymesterone (floo ox" i mes' ter one), stanozolol (stan oh' zoe lol), norethandrolone (nor eth' an droe lone), and oxandrolone (ox an' droe lone), and have been extensively evaluated as a means of increasing weight gain and muscle development in catabolic states as well as to improve athletic performance. They have also been used to treat aplastic anemia and bone marrow failure of several causes. They are often well tolerated and have limited virilizing activity. However, the C-17α alkylated androgenic steroids have all been implicated in cases of liver injury, including prolonged cholestasis, peliosis hepatis, nodular regeneration, hepatic adenomas and hepatocellular carcinoma. In contrast, the C-17β esterified testosterones have only rarely been implicated in causing cholestasis, although their long term use may increase the risk of hepatic tumors and nodular transformation, but seemingly at a much lower rate than the 17α alkylated testosterones. Currently approved uses of androgenic steroids include androgen deficiency, delayed puberty, breast cancer, postpartum breast engorgement, hereditary angioneurotic edema, endometriosis and fibrocystic breast disease. The androgenic steroids are also used off label and illegally as a means of increasing muscle mass and athletic performance. The abuse of anabolic steroids is particularly common among body builders and young male athletes, although their use has been banned from the Olympics and in major professional and college sports. Recently, anabolic steroids have been found in some nutritional supplements available over-the-counter or via the internet which are advertised as increasing a sense of wellbeing and muscle mass or as an aid to body building.</p></div><div id="AndrogenicSteroids.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Androgenic and anabolic steroids have been implicated in four distinct forms of liver injury: transient serum enzyme elevations, an acute cholestatic syndrome (“bland cholestasis”), chronic vascular injury to the liver (peliosis hepatis) and hepatic tumors including adenomas and hepatocellular carcinoma. These adverse events have been most closely linked with the C-17α alkylated testosterones, although tumors have also been associated with unmodified and esterified testosterone preparations.</p><p>Use of androgenic steroids is associated with a variable rate of serum enzyme elevations which are usually asymptomatic and self-limited. Such elevations have been most closely linked to danazol and oxymetholone, but are usually transient and do not require dose adjustment or discontinuation.</p><p>More importantly, therapy with anabolic steroids is linked to a distinctive form of acute cholestasis often referred to as “bland cholestasis”. The liver injury generally arises within 1 to 4 months of starting therapy, but may be delayed to as long as 6 to 24 months (Case 1). The onset is usually insidious with development of nausea, fatigue and itching followed by dark urine and jaundice. Jaundice and pruritus can be prolonged even if the anabolic steroids are discontinued promptly. Typically, serum enzyme elevations are quite modest, with ALT and alkaline phosphatase levels that are less than 2 to 3 times elevated and that are sometimes normal despite deep jaundice. Serum ALT levels may be somewhat high early during injury, but then fall to moderate or low levels. Liver biopsy typically shows a bland cholestasis with minimal inflammation and hepatocellular necrosis. Bile duct injury is typically absent or mild and vanishing bile duct syndrome rarely ensues. The frequency of acute cholestasis from androgenic steroids is not well known, but it is likely somewhat dose related and may occur in ~1% of patients treated with methyltestosterone, danazol, stanozolol or oxymetholone. Cholestasis has not been described in patients receiving unmodified testosterone (by injection or transdermal patch). This clinical phenotype of bland cholestasis is so typical of anabolic steroids, that the diagnosis can be suspected in a patient who denies taking anabolic steroids or who is taking an herbal formulation meant to increase muscle strength or energy and that contains an anabolic steroid even though it is not labelled as such.</p><p>Use of anabolic steroids has also been linked to vascular changes in the liver referred to as peliosis hepatis. Peliosis hepatis is a rare syndrome in which there are blood filled enlarged sinusoids and cysts focally or throughout the liver. There is usually an accompanying sinusoidal dilatation and loss of the normal endothelial barrier. The liver may be enlarged, deep red in color and fragile. Peliosis hepatis most typically occurs in patients with advanced wasting diseases (tuberculosis, cancer), but has also been associated with long term use of anabolic steroid therapy for aplastic anemia and hypogonadism as well as in body building. Serum enzyme levels are usually normal or are mildly and nonspecifically elevated. Patients may present with right upper quadrant discomfort and hepatomegaly or with sudden abdominal pain and vascular collapse due to hepatic rupture and hemoperitoneum. Peliosis may also be an incidental finding found on imaging of the liver or during abdominal surgery or at autopsy. Peliosis associated with anabolic steroids usually reverses, at least in part, with stopping therapy. Peliosis can involve other organs, most typically the spleen.</p><p>The most serious complication of anabolic steroid use is the development of hepatic tumors, either adenoma or hepatocellular carcinoma. The hepatic tumors arise in patients on long term androgenic steroids, usually during therapy of aplastic anemia or hypogonadism, but occasionally in athletes or body builders using anabolic steroids illicitly. Tumors are typically found after 5 to 15 years of use, but onset within 2 years of starting therapy with testosterone esters has been described. Many of the case reports have occurred in patients with other risk factors for cancer, such as Fanconi’s syndrome, iron overload or chronic hepatitis C (from blood transfusions). However, hepatic adenomas and hepatocellular carcinoma have also been described in patients taking androgenic steroids who have no other evidence of liver disease and normal histology in the nontumorous parts of the liver. The pathology of the tumors is usually hepatic adenoma or “well differentiated” hepatocellular carcinoma or hepatic adenoma with areas of malignant transformation. Rare instances of cholangiocarcinoma and angiosarcoma have also been described in patients on long term androgenic steroids. Clinical presentation is generally with right upper quadrant discomfort and a hepatic mass found clinically or on imaging studies. Routine liver tests are often normal unless there is extensive spread or rupture or an accompanying liver disease. Alpha-fetoprotein levels are usually normal. There is often (but not always) spontaneous regression in the tumor when the anabolic steroids are stopped. Hepatocellular carcinoma arising during anabolic steroid therapy is believed to have a better prognosis than that related to cirrhosis or chronic hepatitis B and C; however, deaths from hepatic rupture or tumor spread and metastasis have been reported in patients with anabolic steroid related hepatocellular carcinoma without cirrhosis.</p><p>Finally, nodular regenerative hyperplasia of the liver has been described in rare patients on long term anabolic or androgenic steroids. The condition is usually asymptomatic or associated with mild abdominal discomfort due to hepatomegaly. Rarely, marked nodular regenerative hyperplasia with portal hypertension and splenomegaly has been described. This process may also be related with development of hepatic tumors with androgenic steroids as nodular regeneration is sometimes found in the surrounding “normal” liver.</p></div><div id="AndrogenicSteroids.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The androgens act by engagement of intracellular androgenic steroid receptors which are translocated to the nucleus and bind to androgen response elements on DNA inducing a cassette of androgen stimulated genes that are important in cell growth and development. An unregulated growth stimulus to hepatocytes is the likely cause of nodular regeneration and hepatic tumors related to anabolic steroid use. The cause of cholestasis due to the C-17 substituted androgens is not well defined, but high doses cause a similar cholestasis in some animal models. The syndrome is similar to cholestasis of pregnancy and the jaundice associated with high doses of estrogens or birth control pills and may be due to partial lack or variant of bile salt transporter proteins, as reported in some patients with androgenic anabolic steroid associated cholestasis.</p></div><div id="AndrogenicSteroids.Outcome_and_Managemen"><h3>Outcome and Management</h3><p>The severity of liver injury due to anabolic steroids ranges from minor, transient serum enzyme elevations to profound and prolonged cholestasis, as well as hepatic peliosis and benign and malignant liver tumors. The first priority in management should be stopping the androgenic steroid. Unfortunately, athletes and body builders may resist this recommendation. Merely decreasing the dose of androgenic steroid or switching to another formulation is not appropriate and should be specifically discouraged. Patients being treated for hypogonadism may be switched to an unmodified form of testosterone, given by injection or cutaneous patch. Patients with marked cholestasis may be benefitted by symptomatic therapy of pruritus and fat soluble vitamin supplementation. Ursodiol is often used in drug induced cholestasis, but is efficacy has never been shown in a controlled prospective manner. Use of corticosteroids is usually ineffective and should be avoided. The syndrome is usually reversable with stopping therapy, but full recovery is often delayed. In addition, fatalities have been reported, usually due to marked cholestasis complicated by malnutrition, renal failure and associated opportunistic infections.</p><p>Representative androgenic steroids include the following: danazol, fluoxymesterone, methandienone, methenolone, methyltestosterone, nandrolone, norethandrolone, oxandrolone, oxymetholone, stanozolol, testosterone (cypionate, enanthate, propionate).</p><p>Drug Class: Androgenic Steroids</p></div></div><div id="AndrogenicSteroids.CASE_REPORTS"><h2 id="_AndrogenicSteroids_CASE_REPORTS_">CASE REPORTS</h2><div id="AndrogenicSteroids.Case_1_Cholestasis_du"><h3>Case 1. Cholestasis due to anabolic steroid use.(<a class="bibr" href="#AndrogenicSteroids.REF.1" rid="AndrogenicSteroids.REF.1">1</a>)</h3><p>A 24 year old body builder developed pruritus and jaundice having taken various anabolic steroids for one and a half years. He was also taking several herbal products and dietary supplements including Ma Huang (6% ephedrine), carnitine and chromium. He also drank alcohol, estimating his average intake as one case of beer per day for the last year. He developed dark urine and jaundice and stopped all medications and his alcohol intake promptly. Despite this, he remained jaundiced for a month and had worsening nausea and weight loss and eventually sought medical care. He had no history of liver disease or risk factors for viral hepatitis and took no other medications. On examination, he was muscular and physically fit but deeply jaundiced. He had an enlarged liver but no rash, fever or splenomegaly. Laboratory testing showed a total serum bilirubin of 53 mg/dL, but only modest elevations in serum aminotransferase and a normal alkaline phosphatase level (Table). His prothrombin time was normal. Tests for hepatitis A, B and C were negative. Abdominal ultrasound showed no evidence of biliary obstruction. Liver biopsy was not done. He was treated symptomatically for pruritus with antihistamines, cholestyramine and ursodiol. His jaundice gradually improved and pruritus waned. Six months after the onset of jaundice, he was asymptomatic, had regained most of his weight loss (40 pounds), serum bilirubin was 1.5 mg/dL and serum enzymes were normal.</p><div id="AndrogenicSteroids.Key_Points"><h4>Key Points</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figAndrogenicSteroidsTc"><a href="/books/NBK548931/table/AndrogenicSteroids.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figAndrogenicSteroidsTc" rid-ob="figobAndrogenicSteroidsTc"><img class="small-thumb" src="/books/NBK548931/table/AndrogenicSteroids.Tc/?report=thumb" src-large="/books/NBK548931/table/AndrogenicSteroids.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="AndrogenicSteroids.Tc"><a href="/books/NBK548931/table/AndrogenicSteroids.Tc/?report=objectonly" target="object" rid-ob="figobAndrogenicSteroidsTc">Table</a></h4></div></div></div><div id="AndrogenicSteroids.Laboratory_Values"><h4>Laboratory Values</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figAndrogenicSteroidsTd"><a href="/books/NBK548931/table/AndrogenicSteroids.Td/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figAndrogenicSteroidsTd" rid-ob="figobAndrogenicSteroidsTd"><img class="small-thumb" src="/books/NBK548931/table/AndrogenicSteroids.Td/?report=thumb" src-large="/books/NBK548931/table/AndrogenicSteroids.Td/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="AndrogenicSteroids.Td"><a href="/books/NBK548931/table/AndrogenicSteroids.Td/?report=objectonly" target="object" rid-ob="figobAndrogenicSteroidsTd">Table</a></h4></div></div></div><div id="AndrogenicSteroids.Comment"><h4>Comment</h4><p>A very typical case of severe cholestasis due to anabolic steroid use. Because the steroids were being used without medical supervision, the dose and actual duration of use of each preparation was unclear, but cholestasis usually arises within 4 to 12 weeks of starting a C-17 alkylated androgenic steroid. The jaundice can be severe and prolonged and accompanied by severe pruritus and marked weight loss. The serum enzymes are typically minimally elevated except for a short period immediately after stopping therapy. The pattern of enzyme elevations can be hepatocellular, cholestatic or mixed. Liver biopsy reveals a “bland” cholestasis with minimal inflammation and hepatocellular necrosis. Ma Huang has also been implicated in cases of drug induced liver injury, but is associated with an acute hepatocellular pattern of injury.</p></div></div></div><div id="AndrogenicSteroids.PRODUCT_INFORMATION"><h2 id="_AndrogenicSteroids_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Danazol – Generic,</p><p>Fluoxymesterone – Androxy®,</p><p>Methandienone – Dianabol®</p><p>Methenolone – Primobolan®, Nibal®</p><p>Methyltestosterone – Generic, Android®, Methitest®, Testred®</p><p>Nandrolone – Generic, Deca-Durabolin®</p><p>Norethandrolone – Generic, Nilevar®, Pribabol®</p><p>Oxandrolone – Generic, Oxandrin®</p><p>Oxymetholone – Anadrol®</p><p>Stanozolol – Winstrol®</p><p>Testosterone – Generic, Depo-Testosterone®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Androgenic Steroids</p><p>
|
|
<b>COMPLETE LABELING</b>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=DANAZOL&pagesize=20&page=1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Danazol</a>, <a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=FLUOXYMESTERONE&pagesize=20&page=1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fluoxymesterone</a>, Methandienone, Methenolone, <a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=METHYLTESTOSTERONE&pagesize=20&page=1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Methyltestosterone</a>, <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a586b484-1b46-40b9-9508-fd28002ad383" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Nandrolone</a>, Norethandrolone, <a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=OXANDROLONE&pagesize=20&page=1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Oxandrolone</a>, <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Oxymetholone</a>, Stanozolol, <a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=TESTOSTERONE&pagesize=20&page=1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Testosterone</a></p></div><div id="AndrogenicSteroids.CHEMICAL_FORMULAS_AND"><h2 id="_AndrogenicSteroids_CHEMICAL_FORMULAS_AND_">CHEMICAL FORMULAS AND STRUCTURES</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figAndrogenicSteroidsTe"><a href="/books/NBK548931/table/AndrogenicSteroids.Te/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figAndrogenicSteroidsTe" rid-ob="figobAndrogenicSteroidsTe"><img class="small-thumb" src="/books/NBK548931/table/AndrogenicSteroids.Te/?report=thumb" src-large="/books/NBK548931/table/AndrogenicSteroids.Te/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="AndrogenicSteroids.Te"><a href="/books/NBK548931/table/AndrogenicSteroids.Te/?report=objectonly" target="object" rid-ob="figobAndrogenicSteroidsTe">Table</a></h4></div></div></div><div id="AndrogenicSteroids.CITED_REFERENCE"><h2 id="_AndrogenicSteroids_CITED_REFERENCE_">CITED REFERENCE</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="AndrogenicSteroids.REF.1">Singh C, Bishop P, Wilson R. Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements and ethanol: response to ursodeoxycholic acid treatment. <span><span class="ref-journal">Am J Gastroenterol. </span>1996;<span class="ref-vol">91</span>:783–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8677950" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8677950</span></a>]</div></dd></dl></dl></div><div id="AndrogenicSteroids.ANNOTATED_BIBLIOGRAPH"><h2 id="_AndrogenicSteroids_ANNOTATED_BIBLIOGRAPH_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 30 May 2020</p><p>Abbreviations: HDS, herbal and dietary supplements; BSP, bromosulfophthalein.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="AndrogenicSteroids.REF.zimmerman.1999">Zimmerman HJ. Hormonal derivatives and related drugs. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 555-88.<div><i>(Expert review of effects of androgenic steroids on the liver published in 1999; two forms of hepatic injury occur with anabolic steroids: cholestasis that occurs within the first 6 months associated with the synthetic agents that have an alkyl group in the C17 position, and a delayed injury with vascular or neoplastic changes in which natural androgens can play a role).</i></div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.chitturi.2013">Chitturi S, Farrell GC. Adverse effects of hormones and hormone antagonists on the liver. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 605-20.<div><i>(Review of hepatotoxicity of androgenic steroids including cholestasis, vascular disorders, benign tumors and hepatocellular carcinoma).</i></div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.synder.2018">Synder P. Androgens and the male reproductive tract. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 833-43.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.werner.1950.325">Werner SC, Hanger FM, Kritzler RA. Jaundice during methyltestosterone therapy. <span><span class="ref-journal">Am J Med. </span>1950;<span class="ref-vol">8</span>:325–31.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15404975" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15404975</span></a>]<div>
|
|
<i>(7 patients: 6 men and 1 woman who developed jaundice during oral methyltestosterone therapy, ages 17-67 years, onset after 8 days to 4 months, prodrome of nausea and malaise for 1-2 weeks before jaundice [peak bilirubin 5.1-29 mg/dL, Alk P 1.4 to 4.5 times ULN, albumin normal], lasted 1-3 months; biopsy showed bile stasis with little inflammation; recovery complete; no recurrence upon rechallenge in 3 patients).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.brick.1952.176">Brick IB, Kyle LH. Jaundice of hepatic origin during the course of methyltestosterone therapy. <span><span class="ref-journal">N Engl J Med. </span>1952;<span class="ref-vol">246</span>:176–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14890832" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14890832</span></a>]<div>
|
|
<i>(Two men, ages 44 and 63 years, developed jaundice 7 and 12 weeks after switching from long term testosterone injections to sublingual methyltestosterone [bilirubin not given and 6.8 mg/dL, Alk P 4-5 times ULN], with full but slow recovery after stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.burger.1952.569">Burger RA, Marcuse PM. Peliosis hepatis: report of a case. <span><span class="ref-journal">Am J Clin Pathol. </span>1952;<span class="ref-vol">22</span>:569–73.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14933333" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14933333</span></a>]<div>
|
|
<i>(39 year old woman with metastatic colon cancer and emaciation treated with oral testosterone was found to have peliosis hepatis on autopsy, without endothelial lining and with hepatic necrosis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.lloydthomas.1952.1289">Lloyd-Thomas HG, Sherlock S. Testosterone therapy for the pruritus of obstructive jaundice. <span><span class="ref-journal">Br Med J. </span>1952;<span class="ref-vol">2</span>:1289–91.</span> [<a href="/pmc/articles/PMC2022428/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2022428</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12997743" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12997743</span></a>]<div>
|
|
<i>(Experience in treating 7 patients having intractable itching due to liver disease with methyltestosterone, which led to improvement in itching within 4-7 days but worsening jaundice, serum bilirubin rising by 2.0-9.3 mg/dL).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.almaden.1954.146">Almaden PJ, Ross SW. Jaundice due to methyl testosterone therapy. <span><span class="ref-journal">Ann Intern Med. </span>1954;<span class="ref-vol">40</span>:146–52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13114814" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13114814</span></a>]<div>
|
|
<i>(45 year old woman developed jaundice 7 months after starting methyltestosterone [bilirubin 16.7 mg/dL Alk P slightly elevated], biopsy showing intrahepatic cholestasis and resolution of jaundice within 2 months of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kaplan.1956.384">Kaplan AA. Jaundice due to methyltestosterone therapy. <span><span class="ref-journal">Gastroenterology. </span>1956;<span class="ref-vol">31</span>:384–90.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13365845" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13365845</span></a>]<div>
|
|
<i>(58 year old man developed jaundice and pruritus 6 months after starting sublingual methyltestosterone [bilirubin 13.6 mg/dL, Alk P rising to twice normal], resolving 3 months after stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.koszalka.1957.51">Koszalka MF. Medical obstructive jaundice: report of a death due to methyltestosterone. <span><span class="ref-journal">J Lancet. </span>1957;<span class="ref-vol">77</span>:51–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13398705" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13398705</span></a>]<div>
|
|
<i>(60 year old man with colon cancer developed jaundice 3 weeks after starting methyltestosterone which was continued another 3 weeks [bilirubin 10 mg/dL, Alk P rising to twice normal], with progressive jaundice and death from hepatic failure 2 months after presentation, autopsy showing intrahepatic cholestasis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.peters.1958.114">Peters JH, Randall AH Jr, Mendeloff J, Peace R, Coberly JC, Hurley MB. Jaundice during administration of methylestrenolone. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1958;<span class="ref-vol">18</span>:114–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13491691" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13491691</span></a>]<div>
|
|
<i>(Two of 10 patients receiving 17-methyl-19-nortestosterone for cancer developed jaundice after 4 and 6 weeks of therapy; both died of underlying cancer while still jaundiced).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.seelen.1958.1137">Seelen JC. Complications during administration of methylestrenolone. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1958;<span class="ref-vol">18</span>:1137–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13587633" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13587633</span></a>]<div>
|
|
<i>(Pregnant woman treated with methylestrenolone for habitual abortion developed jaundice 2 months later [bilirubin 19 mg/dL, Alk P 1.5 times ULN], resolving after stopping therapy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kory.1959.243">Kory RC, Bradley MH, Watson RN, Callahan R, Peters BJ. A six-month evaluation of an anabolic drug, norethandrolone, in underweight persons. II. Bromsulphalein (BSP) retention and liver function. <span><span class="ref-journal">Am J Med. </span>1959;<span class="ref-vol">26</span>:243–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13617281" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13617281</span></a>]<div>
|
|
<i>(Prolonged BSP retention found in 74% of samples from 47 patients on norethandrolone for weight gain, returned to normal within a few weeks of stopping; only two patients had mild bilirubin elevations [1.7 and 2.2 mg/dL]).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.schaffner.1959.249">Schaffner F, Popper H, Chesrow E. Cholestasis produced by administration of norethandrolone. <span><span class="ref-journal">Am J Med. </span>1959;<span class="ref-vol">26</span>:249–54.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13617282" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13617282</span></a>]<div>
|
|
<i>(Among 27 patients treated with norethandrolone for nutritional support for 3-5 weeks undergoing liver biopsy before and during therapy, 4 developed cholestasis within 1-5 weeks [bilirubin 32, 1.8, 1.0 and 0.7 mg/dL, AST 190-224 U/L, Alk P 2-20 times ULN], all resolving after stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.foss.1959.259">Foss GL, Simpson SL. Oral methyltestosterone and jaundice. <span><span class="ref-journal">Br Med J. </span>1959;<span class="ref-vol">1</span>:259–63.</span> [<a href="/pmc/articles/PMC1992426/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1992426</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/13618612" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13618612</span></a>]<div>
|
|
<i>(Despite extensive use of methyltestosterone, authors found only one case of jaundice, 60 year old man developed jaundice after 5 weeks of therapy and subsequently died of dehydration and acidosis; summarizes 42 cases from literature; of 5 patients retreated, only one had recurrence).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.shaw.1960.428">Shaw RK, Gold GL. Jaundice associated with norethandrolone(Nilevar) therapy. <span><span class="ref-journal">Ann Intern Med. </span>1960;<span class="ref-vol">52</span>:428–34.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14445654" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14445654</span></a>]<div>
|
|
<i>(60 year old with multiple myeloma developed pruritus after 12 weeks and jaundice after 16 weeks of norethandrolone [bilirubin 9.5 mg/dL, AST 25 U/L, Alk P 3 times ULN], biopsy showed intrahepatic cholestasis, resolving on stopping and prednisone therapy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.wernze.1960.2237">Wernze H. <span><span class="ref-journal">Dtsch med Wschr. </span>1960;<span class="ref-vol">85</span>:2237–42.</span> [Clinical investigation of the problem of liver damage by the newer androgenic and anabolic steroids] German. [<a href="https://pubmed.ncbi.nlm.nih.gov/13784491" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13784491</span></a>]<div>
|
|
<i>(Study of BSP retention in 36 volunteers given C-17 alkylated androgenic steroids; retention rose from <5% to 6-23% within 8-30 days and fell to normal or near normal with 8-10 days thereafter, whereas AST, Alk P and bilirubin levels changed minimally if at all).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kintzen.1960.860">Kintzen W, Silny J. Peliosis hepatic after administration of fluoxymesterone. <span><span class="ref-journal">Can Med Assoc J. </span>1960;<span class="ref-vol">83</span>:860–2.</span> [<a href="/pmc/articles/PMC1938415/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1938415</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/13756172" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13756172</span></a>]<div>
|
|
<i>(60 year old woman with metastatic breast cancer treated with fluoxymesterone for 2 years was found to have peliosis hepatis on autopsy after death from widespread metastatic disease).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.schaffner.1960.623">Schaffner F, Popper H, Perez V. Changes in bile canaliculi produced by norethandrolone: electron microscopic study of human and rat liver. <span><span class="ref-journal">J Lab Clin Med. </span>1960;<span class="ref-vol">56</span>:623–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13747218" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13747218</span></a>]<div>
|
|
<i>(4 patients treated with norethandrolone for 2 weeks underwent liver biopsy which showed “mild nonspecific changes” by light microscopy, but dilated bile canaliculi and shortening of microvilli by electron microscopy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.marquardt.1961.851">Marquardt GH, Fisher CI, Levy P, Dowben RM. Effects of anabolic steroids on liver function tests and creatine excretion. <span><span class="ref-journal">JAMA. </span>1961;<span class="ref-vol">175</span>:851–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13767058" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13767058</span></a>]<div>
|
|
<i>(Six anabolic steroids given to 38 healthy controls for 5 weeks; all led to increase in BSP retention [2.3-17.6%], but no change in bilirubin levels).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.wynn.1961.69">Wynn V, Landon J, Kawarau E. Studies of hepatic function during methandienone therapy. <span><span class="ref-journal">Lancet. </span>1961;<span class="ref-vol">1</span>:69–75.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13786996" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13786996</span></a>]<div>
|
|
<i>(Followed liver tests in 30 patients treated with methandienone; AST elevations occurred in 27% [60-180 U/L], Alk P [2 times ULN] and bilirubin [2.0] in 1, and BSP retention in 62%; all without symptoms and resolving rapidly, some without stopping drug).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.perezmera.1962.1137">Perez-Mera RA, Shields CE. Jaundice associated with norethindrone acetate therapy. <span><span class="ref-journal">N Engl J Med. </span>1962;<span class="ref-vol">267</span>:1137–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13942388" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13942388</span></a>]<div>
|
|
<i>(35 year old woman developed jaundice and abdominal pain 2 years after starting norethindrone for dysmenorrhea [bilirubin 6.5 mg/dL], biopsy showing intrahepatic cholestasis and repeat biopsy 2 months after stopping estrogen showing resolution).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.wilder.1962.768">Wilder EM. Death due to liver failure following the use of methandrostenolone. <span><span class="ref-journal">Can Med Assoc J. </span>1962;<span class="ref-vol">87</span>:768–9.</span> [<a href="/pmc/articles/PMC1849648/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1849648</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14000685" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14000685</span></a>]<div>
|
|
<i>(71 year old woman developed jaundice 8 weeks after starting methandrostenolone for osteoporosis [bilirubin 20.4 mg/dL, AST 200 U/L, Alk P twice normal], with progressive mental obtundation, coagulopathy and death 2 months later, autopsy showing shrunken liver with marked cholestasis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.scherb.1963.404">Scherb J, Kirschner M, Arias IM. Studies of hepatic excretory function. The effect of 17α-ethyl-19-nortestosterone on sulfobromophthalein sodium (BSP) metabolism in man. <span><span class="ref-journal">J Clin Invest. </span>1963;<span class="ref-vol">42</span>:404–8.</span> [<a href="/pmc/articles/PMC289293/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC289293</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/13991599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13991599</span></a>]<div>
|
|
<i>(Prospective study of BSP metabolism in 8 subjects treated with 19-nortestosterone and 10 controls; BSP transport maximum decreased within 7-10 days of starting androgen therapy and returned to normal 1 week afterwards, BSP storage was normal; best explained as a decrease in excretion of conjugated BSP [similar to defect in Dubin-Johnson syndrome).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.gilbert.1963.538">Gilbert EF, DaSilva AQ, Queen DM. Intrahepatic cholestasis with fatal termination following norethandrolone therapy. <span><span class="ref-journal">JAMA. </span>1963;<span class="ref-vol">185</span>:538–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13947807" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13947807</span></a>]<div>
|
|
<i>(74 year old man developed jaundice 5 months after starting norethandrolone but continued for another month and developed delirium [bilirubin 20 mg/dL, AST 475 U/L, Alk P 3 times ULN], dying in hepatic coma; severe cholestasis on autopsy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.marquardt.1964.1334">Marquardt GH, Logan CE, Tomhave WG, Dowben RM. Failure of non-17-alkylated anabolic steroids to produce abnormal liver function tests. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1964;<span class="ref-vol">24</span>:1334–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14243179" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14243179</span></a>]<div>
|
|
<i>(Prospective study of 23 patients given methenolone [non-C-17 substituted synthetic androgen] for weight gain found no change in BSP retention or serum bilirubin levels).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.yanoff.1964.159">Yanoff M, Rawson AJ. Peliosis hepatis: an anatomic study with demonstration of two varieties. <span><span class="ref-journal">Arch Pathol. </span>1964;<span class="ref-vol">77</span>:159–65.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14088761" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14088761</span></a>]<div>
|
|
<i>(Two cases: 73 year old woman with septic arthritis treated with norethandrolone for 6 weeks and 42 year old man with malignant teratoma treated with chemotherapy for 8 months, both found to have peliosis on autopsy; two forms of peliosis, one with and one without endothelial lining, anabolic steroids associated with the latter parenchymal type that also shows bile retention and hepatocyte necrosis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.delorimier.1965.289">DeLorimier AA, Gordan GS, Lowe RC, Carbone JV. Methyltestosterone, related steroids, and liver function. <span><span class="ref-journal">Arch Intern Med. </span>1965;<span class="ref-vol">116</span>:289–94.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14315662" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14315662</span></a>]<div>
|
|
<i>(66 healthy controls were given 9 different 17α-alkylated androgenic steroids or testosterone for 2 weeks; no change in serum bilirubin or Alk P, but most resulted in increased BSP retention, not occurring with non-alkylated testosterone).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.ticktin.1966.674">Ticktin HE, Zimmerman HJ. Effects of synthetic anabolic agent on hepatic function. <span><span class="ref-journal">Am J Med Sci. </span>1966;<span class="ref-vol">251</span>:674–84.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/5946368" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 5946368</span></a>]<div>
|
|
<i>(Prospective analysis of liver tests in 54 patients treated with norbolethone for at least 2 weeks; reversible minor AST elevations in 33% and BSP retention in 66% [both dose related], bilirubin >1.0 mg/dL in 10% and abnormal Alk P in none).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.orlandi.1966.331">Orlandi F, Jezequel AM. On the pathogenesis of the cholestasis induced by C-17 alkylated steroids: ultrastructure and functional changes of the liver cells during treatment. <span><span class="ref-journal">Rev Int Hepatol. </span>1966;<span class="ref-vol">16</span>:331–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/5947852" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 5947852</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.glober.1968.170">Glober GA, Wilkerson JA. Biliary cirrhosis following the administration of methyltestosterone. <span><span class="ref-journal">JAMA. </span>1968;<span class="ref-vol">204</span>:170–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/5694548" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 5694548</span></a>]<div>
|
|
<i>(56 year old woman developed jaundice after taking a nutritional supplement with methyltestosterone and estrone for 4 years with prolonged jaundice [bilirubin 3.2 mg/dL, AST 7 UL, Alk P 54 KA U], evolving into cirrhosis over next 5 years with intractable pruritus and xanthomas; probable primary biliary cirrhosis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF33">Androgens and anabolic steroids. <span><span class="ref-journal">Br Med J. </span>1969;<span class="ref-vol">2</span>:165–7.</span> [<a href="/pmc/articles/PMC1982939/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1982939</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/5778942" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 5778942</span></a>]<div>
|
|
<i>(Review of clinical indications, efficacy and safety of androgenic steroids; mentions that 17α-alkylated androgens can cause jaundice).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.mcgiven.1970.283">McGiven AR. Peliosis hepatis: case report and review of pathogenesis. <span><span class="ref-journal">J Pathol. </span>1970;<span class="ref-vol">101</span>:283–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/5483428" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 5483428</span></a>]<div>
|
|
<i>(75 year old man with rheumatoid arthritis died of an acute myocardial infarction and was found to have peliosis hepatis on autopsy, having received methandienone for the previous year).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.rozman.1971.2605">Rozman C, Urbano A, Galera H. <span><span class="ref-journal">Minerva Med. </span>1971;<span class="ref-vol">62</span>:2605–11.</span> [Hepatotoxicity of anabolic steroids] [<a href="https://pubmed.ncbi.nlm.nih.gov/5566874" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 5566874</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.sansoy.1971.139">Sansoy OM, Roy AN, Shields LM. Anabolic action and side effects of oxandrolone in 34 mental patients. <span><span class="ref-journal">Geriatrics. </span>1971;<span class="ref-vol">26</span>:139–43.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/5549745" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 5549745</span></a>]<div>
|
|
<i>(34 patients were treated with oxandrolone for 2 months to promote weight gain after illness; AST levels increased and were abnormal in 53%, BSP increased in 35%; no patient developed jaundice).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bernstein.1971.1135">Bernstein MS, Hunter RL, Yachnin S. Hepatoma and peliosis hepatis developing in a patient with Fanconi's anemia. <span><span class="ref-journal">N Engl J Med. </span>1971;<span class="ref-vol">284</span>:1135–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4324228" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4324228</span></a>]<div>
|
|
<i>(20 year old with Fanconi anemia developed HCC 1 year after starting oxymetholone with peliosis and multiple intrahepatic hematomas found on autopsy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.johnson.1972.1273">Johnson FL, Feagler JR, Lerner KG, Majerus PW, Siegel M, Hartmann JR, Thomas ED. Association of androgenic-anabolic steroid therapy with the development of hepatocellular carcinoma. <span><span class="ref-journal">Lancet. </span>1972;<span class="ref-vol">2</span>:1273–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4117807" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4117807</span></a>]<div>
|
|
<i>(Description of 4 cases of hepatocellular carcinoma related to C17-alkylated anabolic steroids given for aplastic anemia or Fanconi syndrome, ages 5-27 years taking drugs for 1-7 years; regression of tumor in one with withdrawal; all died within one year).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.guy.1973.148">Guy JT, Auslander MO. Androgenic steroids and hepatocellular carcinoma. <span><span class="ref-journal">Lancet. </span>1973;<span class="ref-vol">1</span>:148.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4118484" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4118484</span></a>]<div>
|
|
<i>(38 year old man with Fanconi’s syndrome had hepatocellular carcinoma on autopsy with mildly abnormal liver tests; had received androgenic steroids for 4 months at age 14).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.henderson.1973.934">Henderson JT, Richmond J, Sumerling MD. Androgenic-anabolic steroid therapy and hepatocellular cancer. <span><span class="ref-journal">Lancet. </span>1973;<span class="ref-vol">1</span>:934.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4123858" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4123858</span></a>]<div>
|
|
<i>(12 year old male with aplastic anemia developed hepatocellular carcinoma having received 8 years of intermittent anabolic steroid therapy and many transfusions).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF41">Liver tumours and steroid hormones. <span><span class="ref-journal">Lancet. </span>1973;<span class="ref-vol">2</span>:1481–2.</span> Editorial. [<a href="https://pubmed.ncbi.nlm.nih.gov/4129317" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4129317</span></a>]<div>
|
|
<i>(Editorial discussing the development of cholestasis, peliosis, adenoma and hepatocellular carcinoma after anabolic and contraceptive steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.jackson.1973.481">Jackson ST, Rallison ML, Buntin WH, Johnson SB, Flynn RR. Use of oxandrolone for growth stimulation in children. <span><span class="ref-journal">Am J Dis Child. </span>1973;<span class="ref-vol">126</span>:481–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4361338" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4361338</span></a>]<div>
|
|
<i>(9 children with constitutional growth retardation treated with oxandrolone for 2 6-month periods with careful monitoring; no clinical or laboratory evidence of liver injury; one patient had increase in BSP retention).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.presant.1973.175">Presant CA, Safdar SH. Oxymetholone in myelofibrosis and chronic lymphocytic leukemia. <span><span class="ref-journal">Arch Intern Med. </span>1973;<span class="ref-vol">132</span>:175–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4719544" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4719544</span></a>]<div>
|
|
<i>(Among 9 patients with refractory anemia, oxymetholone decreased transfusion requirements; 4 developed hepatotoxicity after 3-6 months, mild jaundice in 1 [bilirubin 3.1 mg/dL], mild Alk P or AST elevations in others, most resolved despite continuing medication).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.ziegenfuss.1973.262">Ziegenfuss J, Carabasi R. Androgens and hepatocellular carcinoma. <span><span class="ref-journal">Lancet. </span>1973;<span class="ref-vol">1</span>:262.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4119402" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4119402</span></a>]<div>
|
|
<i>(68 year old man treated with methyltestosterone for 30 years for impotence presented with abdominal pain and hepatocellular carcinoma which was “almost completely” resected).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.frasier.1973.479">Frasier SD. Androgens and athletes. <span><span class="ref-journal">Am J Dis Child. </span>1973;<span class="ref-vol">125</span>:479–80.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4699885" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4699885</span></a>]<div>
|
|
<i>(Editorial criticizing use of anabolic steroids to improve athletic performance).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.naeim.1973.284">Naeim F, Copper PH, Seminion AA. Peliosis hepatis: possible etiologic role of anabolic steroids. <span><span class="ref-journal">Arch Pathol. </span>1973;<span class="ref-vol">95</span>:284–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4348726" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4348726</span></a>]<div>
|
|
<i>(Two cases of peliosis found on autopsy; a child with Fanconi’s anemia who had developed jaundice after a short course of fluoxymesterone; a 65 year old woman on hormone replacement therapy for 18 months who died of congestive heart failure).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bagheri.1974.610">Bagheri SA, Boyer JL. Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury. <span><span class="ref-journal">Ann Intern Med. </span>1974;<span class="ref-vol">81</span>:610–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4423214" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4423214</span></a>]<div>
|
|
<i>(Seven patients on anabolic steroids for 2 to 27 months developed peliosis, 2 developing hemorrhage, 3 hepatic failure and 2 renal failure; serum bilirubin levels as high as 34.6 mg/dL, Alk P 1-20 times elevated, AST 30 to 950 U/L).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.groos.1974.874">Groos G, Arnold OH, Brittinger G. Letter: Peliosis hepatis after long-term administration of oxymetholone. <span><span class="ref-journal">Lancet. </span>1974;<span class="ref-vol">1</span>:874.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4132832" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4132832</span></a>]<div>
|
|
<i>(33 year old woman with aplastic anemia developed hepatomegaly [bilirubin 6.6 mg//dL, ALT 243 U/L, Alk P 229 U/L] 1.5 years after starting oxymetholone, liver size decreasing when drug was stopped).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.cattan.1974.878">Cattan D, Vesin P, Wautier J, Kalifat R, Meignan S. Liver tumors and steroid hormones. <span><span class="ref-journal">Lancet. </span>1974;<span class="ref-vol">1</span>:878.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4132843" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4132843</span></a>]<div>
|
|
<i>(7 year old girl with Fanconi’s anemia developed hepatocellular carcinoma but had never received androgenic steroids, instead had transfusion-attributed hemosiderosis and cirrhosis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.meadows.1974.109">Meadows AT, Naiman JL, Valdes-Dapena MV. Hepatoma associated with androgen therapy for aplastic anemia. <span><span class="ref-journal">J Pediatr. </span>1974;<span class="ref-vol">84</span>:109–10.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12119927" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12119927</span></a>]<div>
|
|
<i>(6 year old girl with aplastic anemia on androgens for 3.5 years died of intracranial hemorrhage and was found to have hepatocellular carcinoma on autopsy; the liver was enlarged but liver tests were all normal).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.mulvihill.1975.122">Mulvihill JJ, Ridolfi RL, Schultz FR, Borzy MS, Haughton PB. Hepatic adenoma in Fanconi anemia treated with oxymetholone. <span><span class="ref-journal">J Pediatr. </span>1975;<span class="ref-vol">87</span>:122–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/168333" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 168333</span></a>]<div>
|
|
<i>(12 year old boy with Fanconi’s anemia treated with oxymetholone developed jaundice [bilirubin 23 mg/dL and “liver function abnormalities”], improving when oxymetholone was stopped; on autopsy after intracerebral bleed found to have 9 cm hepatic adenoma “with distant metastases”).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.sarna.1975.1029">Sarna G, Tomasulo P, Lotz MJ, Bubinak JF, Shulman NR. Multiple neoplasms in two siblings with a variant form of Fanconi's anemia. <span><span class="ref-journal">Cancer. </span>1975;<span class="ref-vol">36</span>:1029–33.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/171048" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 171048</span></a>]<div>
|
|
<i>(Two brothers with Fanconi’s anemia on long term androgen therapy both developed malignancies, including leukemia, gingival squamous cell cancer, and hepatocellular carcinoma).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.k_hb_ck.1975.1602">Kühböck J, Radaszkiewicz T, Walek H. <span><span class="ref-journal">Med Klin. </span>1975;<span class="ref-vol">70</span>:1602–7.</span> [Peliosis hepatis, complicating treatment with anabolic steroids (author's transl)] German. [<a href="https://pubmed.ncbi.nlm.nih.gov/810650" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 810650</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.ball.1975.91">Ball JH, Lowrie EG, Hampers CL, Merrill JP. Testosterone therapy in hemodialysis patients. <span><span class="ref-journal">Clin Nephrol. </span>1975;<span class="ref-vol">4</span>:91–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1183099" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1183099</span></a>]<div>
|
|
<i>(30 patients on chronic hemodialysis were treated with testosterone injections for anemia; AST elevations occurred in both treated and untreated controls).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.farrell.1975.430">Farrell GC, Joshua DE, Uren RF, Baird PJ, Perkins KW, Kronenberg H. Androgen-induced hepatoma. <span><span class="ref-journal">Lancet. </span>1975;<span class="ref-vol">1</span>:430–2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/48615" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 48615</span></a>]<div>
|
|
<i>(Three cases of hepatocellular carcinoma in men on androgenic steroids, ages 28 to 40 years, on oxymetholone or methyltestosterone for 5-8 years, liver and tumor size decreasing on stopping androgenic steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.anthony.1975.685">Anthony PP. Hepatoma associated with androgenic steroids. <span><span class="ref-journal">Lancet. </span>1975;<span class="ref-vol">1</span>:685–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/47110" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 47110</span></a>]<div>
|
|
<i>(Letter in response to Farrell [1975] stressing the poor prognosis of hepatocellular carcinoma; median survival time being 1 month and raising a question of the accuracy of the diagnosis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bakker.1976.2214">Bakker K, Brouwers TM, Houthoff HJ, Postma A. <span><span class="ref-journal">Ned Tijdschr Geneeskd. </span>1976;<span class="ref-vol">120</span>:2214–20.</span> [Liver lesions due to long-term use of anabolic steroids and oral contraceptives] Dutch. [<a href="https://pubmed.ncbi.nlm.nih.gov/1012379" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1012379</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kew.1976.1233">Kew MC, Van Coller B, Prowse CM, Skikne B, Wolfsdorf JI, Isdale J, Krawitz S, et al. Occurrence of primary hepatocellular cancer and peliosis hepatis after treatment with androgenic steroids. <span><span class="ref-journal">S Afr Med J. </span>1976;<span class="ref-vol">50</span>:1233–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/184552" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 184552</span></a>]<div>
|
|
<i>(3 cases of complications of androgenic steroids: 34 year old woman with Fanconi’s anemia developed hepatocellular carcinoma after 7 years of therapy with methyltestosterone and 2 children [1 girl and 1 boy] developed peliosis hepatis, 5 and 8 years after starting androgenic steroids, both died soon after diagnosis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kessler.1976.521">Kessler E, Bar-Meir S, Pinkhas J. <span><span class="ref-journal">Harefuah. </span>1976;<span class="ref-vol">90</span>:521–4.</span> [Focal nodular hyperplasia and spontaneous hepatic rupture in aplastic anemia treated with oxymetholone] Hebrew. [<a href="https://pubmed.ncbi.nlm.nih.gov/964746" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 964746</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.boyer.1976.461">Boyer JL, Preisig R, Zbinden G, de Kretser DM, Wang C, Paulsen CA. Guidelines for assessment of potential hepatotoxic effects of synthetic androgens, anabolic agents and progestogens in their use in males as antifertility agents. <span><span class="ref-journal">Contraception. </span>1976;<span class="ref-vol">13</span>:461–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/767052" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 767052</span></a>]<div>
|
|
<i>(Recommendations for monitoring for hepatotoxicity in trials of anabolic steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.hast.1976.90">Hast R, Skårberg KO, Engstedt L, Jameson S, Killander A, Lundh B, Reizenstein P, et al. Oxymetholone treatment in aregenerative anaemia. II. Remission and survival—a prospective study. <span><span class="ref-journal">Scand J Haematol. </span>1976;<span class="ref-vol">16</span>:90–100.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1257703" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1257703</span></a>]<div>
|
|
<i>(53 patients with anemia due to bone marrow insufficiency were treated with oxymetholone for at least 6 months; 3 developed jaundice requiring discontinuation).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.hervey.1976.699">Hervey GR, Hutchinson I, Knibbs AV, Burkinshaw L, Jones PR, Norgan NG, Levell MJ. "Anabolic" effects of methandienone in men undergoing athletic training. <span><span class="ref-journal">Lancet. </span>1976;<span class="ref-vol">2</span>:699–702.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/61389" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 61389</span></a>]<div>
|
|
<i>(Double-blind crossover study of 6 weeks of methandienone in 11 male athletes; no change in bilirubin, ALT, AST or Alk P levels during drug period).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.lesna.1976.1124">Lesna M, Spencer I, Walker W. Liver nodules and androgens. <span><span class="ref-journal">Lancet. </span>1976;<span class="ref-vol">1</span>:1124.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/57524" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 57524</span></a>]<div>
|
|
<i>(17 year old male with long standing aplastic anemia treated with oxymetholone developed sudden rupture of right lobe of liver and autopsy revealed multiple hepatic nodules and adenomas).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.slater.1976.229">Slater SD, Davidson JF, Patrick RS. Jaundice induced by stanozolol hypersensitivity. <span><span class="ref-journal">Postgrad Med J. </span>1976;<span class="ref-vol">52</span>:229–32.</span> [<a href="/pmc/articles/PMC2496182/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2496182</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1273017" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1273017</span></a>]<div>
|
|
<i>(66 year old man developed jaundice 7 months after starting stanozolol [bilirubin 8.0 mg/dL, ALT 74 U/L, Alk P 3 times ULN], with biopsy showing cholestasis but conspicuous eosinophils suggesting “hypersensitivity” with slow resolution over ensuing 6 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.sweeney.1976.626">Sweeney EC, Evans DJ. Hepatic lesions in patients treated with synthetic anabolic steroids. <span><span class="ref-journal">J Clin Pathol. </span>1976;<span class="ref-vol">29</span>:626–33.</span> [<a href="/pmc/articles/PMC476130/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC476130</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/185239" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 185239</span></a>]<div>
|
|
<i>(Three cases of liver injury due to anabolic steroids; 8 year old boy with Fanconi’s syndrome developed hepatocellular carcinoma after 3 years of methyltestosterone therapy; 46 year old man with severe, ultimately fatal cholestasis [bilirubin 9.8 mg/dL, AST 102 U/L, Alk P 1510 U/L] 3 months after starting oxymetholone; 31 year old woman with aplastic anemia died of intracerebral bleeding after 3 months of oxymetholone therapy and had regenerative hepatic nodules on autopsy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.tso.1977.513">Tso SC, Chan TK, Todd D. Aplastic anaemia: a study of prognosis and the effect of androgen therapy. <span><span class="ref-journal">Q J Med. </span>1977;<span class="ref-vol">46</span>:513–29.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/594300" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 594300</span></a>]<div>
|
|
<i>(129 cases of aplastic anemia from Hong Kong between 1955-74; 75 received androgen therapy, among whom 12 [16%] had ALT elevations, 7 [10%] jaundice and 2 died with persistent jaundice).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.young.1977.47">Young GP, Bhathal PS, Sullivan JR, Wall AJ, Fone DJ, Hurley TH. Fatal hepatic coma complicating oxymetholone therapy in multiple myeloma. <span><span class="ref-journal">Aust N Z J Med. </span>1977;<span class="ref-vol">7</span>:47–51.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/266893" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 266893</span></a>]<div>
|
|
<i>(Two patients, 56 year old woman and 60 year old man developed severe jaundice 6 and 8 weeks after starting oxymetholone for multiple myeloma [bilirubin 11.7 and 21.9 mg/dL, AST normal, Alk P 286 and 700 U/L], with progressive jaundice, renal failure, hepatic encephalopathy and death within 4-6 weeks of presentation).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.leong.1977.537">Leong AS, Sage RE. Drug-induced hepatic injury. <span><span class="ref-journal">Aust N Z J Med. </span>1977;<span class="ref-vol">7</span>:537–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/272174" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 272174</span></a>]<div>
|
|
<i>(Letter in response to Young [1977] describing 76 year old woman who developed jaundice while receiving oxymetholone and was continued for 3 months [bilirubin 6.2 mg/dL, ALT 346 U/L, Alk P 116 U/L], followed by hepatic failure but biopsy showed marked cholestasis with little necrosis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bhathal.1977.539">Bhathal PS, Fone DJ, Hurley TH, Sullivan JR, Wall AJ, Young GP. Drug-induced hepatic injury. <span><span class="ref-journal">Aust N Z J Med. </span>1977;<span class="ref-vol">7</span>:539–40.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/272175" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 272175</span></a>]<div>
|
|
<i>(Reply to Leong and Sage [1977]; retrospective review of 27 patients with multiple myeloma treated with oxymetholone identified 9 [47%] who developed jaundice).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.nadell.1977.405">Nadell J, Kosek J. Peliosis hepatis. Twelve cases associated with oral androgen therapy. <span><span class="ref-journal">Arch Pathol Lab Med. </span>1977;<span class="ref-vol">101</span>:405–10.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/577673" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 577673</span></a>]<div>
|
|
<i>(12 patients with peliosis who had received oral androgens for 3 to 24 months from a single institution; 3 died of hepatic failure related to peliosis, one had diagnosis by biopsy and peliosis resolved with stopping androgens, 8 others found incidentally on autopsy; also reviewed 42 cases of peliosis in English literature).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bird.1977.400">Bird DR, Vowles KDJ. Liver damage from long-term methyltestosterone. <span><span class="ref-journal">Lancet. </span>1977;<span class="ref-vol">2</span>:400–1.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/70606" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 70606</span></a>]<div>
|
|
<i>(39 year old transsexual treated with methyltestosterone for 7 years developed sudden hepatic rupture due to peliosis hepatis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.westaby.1977.262">Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. <span><span class="ref-journal">Lancet. </span>1977;<span class="ref-vol">2</span>:262–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/69876" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 69876</span></a>]<div>
|
|
<i>(Among 60 patients on long term methyltestosterone, 32% had raised AST, 55% abnormal liver scan; liver biopsies in 11 showed sinusoidal dilatation in 9 and cholestasis in 3 [one with bilirubin of 1.7 mg/dL] and one developed adenoma).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.mokrohisky.1977.1411">Mokrohisky ST, Ambruso DR, Hathaway WE. Fulminant hepatic neoplasia after androgen therapy. <span><span class="ref-journal">N Engl J Med. </span>1977;<span class="ref-vol">296</span>:1411–2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/193011" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 193011</span></a>]<div>
|
|
<i>(6 year old girl with Fanconi’s anemia developed hepatomegaly 2 months after starting oxymetholone with hepatocellular carcinoma in a noncirrhotic liver, dying 5 weeks after diagnosis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.boyd.1977.1765">Boyd PR, Mark GJ. Multiple hepatic adenomas and a hepatocellular carcinoma in a man on oral methyl testosterone for 11 years. <span><span class="ref-journal">Cancer. </span>1977;<span class="ref-vol">40</span>:1765–70.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/198106" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 198106</span></a>]<div>
|
|
<i>(29 year old man developed multiple hepatic adenomas and hepatocellular carcinoma 12 years after starting oral methyltestosterone for hypopituitarism).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.sale.1977.600">Sale GE, Lerner KG. Multiple tumors after androgen therapy. <span><span class="ref-journal">Arch Pathol Lab Med. </span>1977;<span class="ref-vol">101</span>:600–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/199136" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 199136</span></a>]<div>
|
|
<i>(37 year old man with aplastic anemia developed hepatocellular carcinoma and peliosis hepatis as well as pancreatic and renal tumors after 5 years of anabolic steroid therapy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.hernandeznieto.1977.1761">Hernandez-Nieto L, Bruguera M, Bombi J, Camacho L, Rozman C. Benign liver-cell adenoma associated with long-term administration of an androgenic-anabolic steroid (methandienone). <span><span class="ref-journal">Cancer. </span>1977;<span class="ref-vol">40</span>:1761–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/198105" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 198105</span></a>]<div>
|
|
<i>(19 year old man presented with two hepatic adenomas, one of which ruptured after 3 years of methandienone therapy for paroxysmal nocturnal hemoglobinuria).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.paradinas.1977.225">Paradinas FJ, Bull TB, Westaby D, Murray-Lyon IM. Hyperplasia and prolapse of hepatocytes into hepatic veins during longterm methyltestosterone therapy: possible relationships of these changes to the development of peliosis hepatis and liver tumours. <span><span class="ref-journal">Histopathology. </span>1977;<span class="ref-vol">1</span>:225–46.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/615837" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 615837</span></a>]<div>
|
|
<i>(Liver histology from 11 patients treated with methyltestosterone for up to 3 years [ALT abnormal in 6 patients, range 53-246 U/L], found sinusoidal dilatation in most cases and “microcysts” with hyperplasia of hepatocytes that partially occluded the sinusoidal or hepatic vein lumens).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.shapiro.1977.1104">Shapiro P, Ikeda RM, Ruebner BH, Connors MH, Halsted CC, Abildgaard CF. Multiple hepatic tumors and peliosis hepatis in Fanconi's anemia treated with androgens. <span><span class="ref-journal">Am J Dis Child. </span>1977;<span class="ref-vol">131</span>:1104–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/199056" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 199056</span></a>]<div>
|
|
<i>(13 year old boy with Fanconi’s anemia, who was treated with oxymetholone for 5-6 years, died of septicemia and was found to have hepatocellular carcinoma and peliosis hepatis on autopsy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.coombes.1978.869">Coombes GB, Reiser J, Paradinas FJ, Burn I. An androgen-associated hepatic adenoma in a trans-sexual. <span><span class="ref-journal">Br J Surg. </span>1978;<span class="ref-vol">65</span>:869–70.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/737424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 737424</span></a>]<div>
|
|
<i>(27 year old woman transsexual treated with methyltestosterone for 3 years presented with abdominal pain and was found to have an hepatic adenoma with hemorrhage; no follow up provided).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.mcdonald.1978.243">McDonald EC, Speicher CE. Peliosis hepatis associated with administration of oxymetholone. <span><span class="ref-journal">JAMA. </span>1978;<span class="ref-vol">240</span>:243–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/666906" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 666906</span></a>]<div>
|
|
<i>(26 year old man with Hodgkin’s disease developed jaundice 2 months after starting oxymetholone [bilirubin 6.0 mg/dL, AST ~50 U/L, Alk P ~350 U/L], progressing to liver decompensation and death from sepsis, autopsy showing peliosis hepatis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.taxy.1978.331">Taxy JB. Peliosis: a morphologic curiosity becomes an iatrogenic problem. <span><span class="ref-journal">Hum Pathol. </span>1978;<span class="ref-vol">9</span>:331–40.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/658966" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 658966</span></a>]<div>
|
|
<i>(Five cases of peliosis hepatis in patients [4 men and 1 woman, ages 35 to 71 years] on anabolic steroids for 3 months to 3 years for cancer or bone marrow disease, several with splenic involvement and one fatal).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.leblay.1978.1026">Leblay R, Brissot P, leCalve JL, Ferrand B. <span><span class="ref-journal">Nouv Presse Med. </span>1978;<span class="ref-vol">7</span>:1026.</span> [Peliosis hepatis after treatment with androgens. A recent case] [<a href="https://pubmed.ncbi.nlm.nih.gov/662612" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 662612</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.benjamin.1978.207">Benjamin DR, Shunk B. A fatal case of peliosis of the liver and spleen. <span><span class="ref-journal">Am J Dis Child. </span>1978;<span class="ref-vol">132</span>:207–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/626188" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 626188</span></a>]<div>
|
|
<i>(15 year old male with aplastic anemia treated with oxymetholone for 5 years developed sudden intraperitoneal bleeding from splenic peliosis and a capsular tear).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.stromeyer.1979.440">Stromeyer FW, Smith DH, Ishak KG. Anabolic steroid therapy and intrahepatic cholangiocarcinoma. <span><span class="ref-journal">Cancer. </span>1979;<span class="ref-vol">43</span>:440–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/217519" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 217519</span></a>]<div>
|
|
<i>(47 year old man developed an hepatic tumor and progressive hepatic failure 2 years after starting oxymetholone therapy for refractory anemia; autopsy showed cholangiocarcinoma).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.arnold.1979.213">Arnold GL, Kaplan MM. Peliosis hepatis due to oxymetholone—a clinically benign disorder. <span><span class="ref-journal">Am J Gastroenterol. </span>1979;<span class="ref-vol">71</span>:213–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/433907" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 433907</span></a>]<div>
|
|
<i>(67 year old man with sideroblastic anemia treated with oxymetholone for 2 years developed jaundice [bilirubin 4.9 mg/dL, ALT 81 U/L, Alk P normal], biopsy showing cholestasis and peliosis, resolving within 2 months of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.karasawa.1979.457">Karasawa T, Shikata T, Smith RD. Peliosis hepatitis: report of nine cases. <span><span class="ref-journal">Acta Pathol Jpn. </span>1979;<span class="ref-vol">29</span>:457–69.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/582233" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 582233</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.falk.1979.1120">Falk H, Thomas LB, Popper H. Hepatic angiosarcoma associated with androgenic-anabolic steroids. <span><span class="ref-journal">Lancet. </span>1979;<span class="ref-vol">2</span>:1120–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/91848" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 91848</span></a>]<div>
|
|
<i>(Among 168 cases of angiosarcoma identified in a US retrospective study [1964-74], 4 had received anabolic steroids for 1-23 years).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.scheuer.1979.779">Scheuer A, Gerdes H, Lehmann FG. <span><span class="ref-journal">Dtsch Med Wochenschr. </span>1979;<span class="ref-vol">104</span>:779–83.</span> [Anabolic agents and liver neoplasms] German. [<a href="https://pubmed.ncbi.nlm.nih.gov/446297" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 446297</span></a>]<div>
|
|
<i>(Review of association of anabolic steroids and liver tumors; animal studies suggest that androgens promote liver tumor growth and in humans the association has been best shown in patients with a predisposition to liver cancer [Fanconi’s anemia and chronic hepatitis]).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.treuner.1980.952">Treuner J, Niethammer D, Flach A, Fischbach H, Schenck W. <span><span class="ref-journal">Med Welt. </span>1980;<span class="ref-vol">31</span>:952–5.</span> [Hepatocellular carcinoma following oxymetholone treatment] [<a href="https://pubmed.ncbi.nlm.nih.gov/6252413" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6252413</span></a>]<div>
|
|
<i>(16 year old boy with aplastic anemia was treated with oxymetholone for 6 years and presented with hepatocellular carcinoma that could not be completely resected but that regressed with stopping androgens).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.montgomery.1980.90">Montgomery RR, Ducore JM, Githens JH, August CS, Johnson ML. Regression on oxymetholone-induced hepatic tumors after bone marrow transplantation in aplastic anemia. <span><span class="ref-journal">Transplantation. </span>1980;<span class="ref-vol">30</span>:90–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7010713" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7010713</span></a>]<div>
|
|
<i>(13 year old boy with aplastic anemia responded to oxymetholone therapy but developed multiple hepatic tumors 3 years later; underwent bone marrow transplant when aplastic anemia relapsed and over next 3 years liver tumors completely regressed).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.wright.1980.149">Wright JE. Anabolic steroids and athletics. <span><span class="ref-journal">Exerc Sport Sci Rev. </span>1980;<span class="ref-vol">8</span>:149–202.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7016547" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7016547</span></a>]<div>
|
|
<i>(Review of literature on effects of anabolic steroids on increasing athletic performance as well as side effects).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.pearson.1980.645">Pearson K, Zimmerman HJ. Danazol and liver damage. <span><span class="ref-journal">Lancet. </span>1980;<span class="ref-vol">1</span>:645–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6102641" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6102641</span></a>]<div>
|
|
<i>(Five patients, 4 women and 1 man, ages 13 to 34 years, developed abnormal liver tests 1-5 months after starting danazol for endometriosis or angioneurotic edema [ALT 61-126 U/L, AST 81-290 U/L], one had jaundice, but limited details provided).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.saheb.1980.432">Saheb F. Absence of peliosis hepatis in patients receiving testosterone enanthate. <span><span class="ref-journal">Hepatogastroenterology. </span>1980;<span class="ref-vol">27</span>:432–40.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7203375" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7203375</span></a>]<div>
|
|
<i>(Among 52 patients with renal failure who had received testosterone enanthate for anemia, none had peliosis or liver tumors on autopsy, suggesting that natural forms of testosterone do not lead to these complications).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.wilson.1980.1278">Wilson JD, Griffin JE. The use and misuse of androgens. <span><span class="ref-journal">Metabolism. </span>1980;<span class="ref-vol">29</span>:1278–95.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7005620" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7005620</span></a>]<div>
|
|
<i>(Three types of modifications of testosterone molecule improve its duration of action [β-esterification], improve its oral bioavailability [17α-alkylation], or increase its activity [ring modification]; the 17α-alkylated modifications can cause liver disease).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.pecking.1980.257">Pecking A, Lejolly JM, Najean Y. <span><span class="ref-journal">Nouv Rev Fr Hematol. </span>1980;<span class="ref-vol">22</span>:257–65.</span> [Hepatotoxicity of androgens in the course of therapy of aplastic anemia] [<a href="https://pubmed.ncbi.nlm.nih.gov/6782550" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6782550</span></a>]<div>
|
|
<i>(254 patients with aplastic anemia were treated with androgens and monitored for up to 8 years; 17% developed jaundice and another 18% had liver test abnormalities without jaundice; no severe liver injury or cirrhosis recorded but 2 developed hepatic adenomas [after 20-21 months]).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.zevin.1981.274">Zevin D, Turani H, Cohen A, Levi J. Androgen-associated hepatoma in a hemodialysis patient. <span><span class="ref-journal">Nephron. </span>1981;<span class="ref-vol">29</span>:274–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6275283" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6275283</span></a>]<div>
|
|
<i>(68 year old man on hemodialysis was treated with oxymetholone for 18 months and nandrolone for 18 months when he presented with large hepatic mass, dying two weeks later; hepatocellular carcinoma but no cirrhosis on autopsy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.cocks.1981.617">Cocks JR. Methyltestosterone-induced liver-cell tumours. <span><span class="ref-journal">Med J Aust. </span>1981;<span class="ref-vol">2</span>:617–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6278274" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6278274</span></a>]<div>
|
|
<i>(51 year old man on methyltestosterone for 20 years because of infertility developed hepatic rupture due to hepatocellular carcinoma with regression of mass on stopping androgens).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.ishak.1981.116">Ishak KG. Hepatic lesions caused by anabolic and contraceptive steroids. <span><span class="ref-journal">Semin Liver Dis. </span>1981;<span class="ref-vol">1</span>:116–28.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6287645" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6287645</span></a>]<div>
|
|
<i>(Review of effects of male and female sex hormones on the liver including biochemical changes, subcellular alternations, cholestasis, vascular disorders, hyperplasia, neoplasia and miscellaneous).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.stromeyer.1981.60">Stromeyer FW, Ishak KG. Nodular transformation (nodular “regenerative hyperplasia”) of the liver: a clinicopathologic study of 30 cases. <span><span class="ref-journal">Hum Pathol. </span>1981;<span class="ref-vol">12</span>:60–71.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7203455" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7203455</span></a>]<div>
|
|
<i>(Analysis of 30 cases of nodular regenerative hyperplasia from the files of the Armed Forces Institute of Pathology; half men, ages 14 to 80 years, variable presentations, 15 died, some of hepatic failure; AST and Alk P mildly elevated; associated diseases included polycythemia vera, rheumatoid arthritis, lymphoproliferative disorders, renal transplantation and autoimmune diseases; associated medications included prednisone, azathioprine, OCCs, and immunosuppressive agents).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.westaby.1983.1947">Westaby D, Portmann B, Williams R. Androgen-related primary hepatic tumors in non-Fanconi patients. <span><span class="ref-journal">Cancer. </span>1983;<span class="ref-vol">51</span>:1947–52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6299502" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6299502</span></a>]<div>
|
|
<i>(Three men, ages 28 to 58 years, developed hepatocellular carcinoma after 10-17 years of methyltestosterone therapy for hypogonadism, with some degree of regression upon stopping anabolic steroid).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.turani.1983.332">Turani H, Levi J, Zevin D, Kessler E. Hepatic lesions in patients on anabolic androgenic therapy. <span><span class="ref-journal">Isr J Med Sci. </span>1983;<span class="ref-vol">19</span>:332–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6853130" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6853130</span></a>]<div>
|
|
<i>(11 men on long term androgenic steroids had abnormal liver findings; 3 were found to have carcinoma [hepatocellular and cholangiocarcinoma] and 8 peliosis hepatis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.c_p.1983.73">Cáp J, Ondrus B, Danihel L. <span><span class="ref-journal">Bratisl Lek Listy. </span>1983;<span class="ref-vol">79</span>:73–81.</span> [Focal nodular hyperplasia of the liver and hepatocellular carcinoma of the liver in children with Fanconi's anemia after long-term treatment with androgens] Slovak. [<a href="https://pubmed.ncbi.nlm.nih.gov/6297692" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6297692</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.malt.1983.247">Malt RA, Galdabini JJ, Jeppsson BW. Abnormal sex-steroid milieu in young adults with hepatocellular carcinoma. <span><span class="ref-journal">World J Surg. </span>1983;<span class="ref-vol">7</span>:247–52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6306934" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6306934</span></a>]<div>
|
|
<i>(Among 7 patients ages 20-30 years with hepatocellular carcinoma seen over 15 year period, 2 were men on methyltestosterone in whom the tumor regressed on stopping androgens, and they were alive 2 and 7 years later).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.schmidt.1984.452">Schmidt E, Deeg HJ, Storb R. Regression of androgen-related hepatic tumors in patients with Fanconi's anemia following marrow transplantation. <span><span class="ref-journal">Transplantation. </span>1984;<span class="ref-vol">37</span>:452–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6375000" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6375000</span></a>]<div>
|
|
<i>(Two patients with Fanconi’s anemia [1 girl, 1 boy] developed liver disease and hepatic masses after being treated with oxymetholone for 4 and 11 years; after bone marrow transplantation the masses regressed as documented by serial imaging studies).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.chandra.1984.168">Chandra RS, Kapur SP, Kelleher J Jr, Luban N, Patterson K. Benign hepatocellular tumors in the young. A clinicopathologic spectrum. <span><span class="ref-journal">Arch Pathol Lab Med. </span>1984;<span class="ref-vol">108</span>:168–71.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6320760" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6320760</span></a>]<div>
|
|
<i>(Seven children with hepatocellular carcinoma without cirrhosis [some had fibrosis] included 4 with aplastic or Fanconi’s anemia who had received oxymetholone for 3 to 8 years; other 3 were found to have cancer incidentally on autopsy, two with thalassemia and one post-renal transplant).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.peces.1984.1505">Peces R, Ablanedo P, Alvarez J. Peliosis hepatis after renal transplantation. <span><span class="ref-journal">Arch Intern Med. </span>1984;<span class="ref-vol">144</span>:1505.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6375618" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6375618</span></a>]<div>
|
|
<i>(Patient on hemodialysis received androgenic steroids for 2 years developed peliosis hepatis with portal hypertension).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.overly.1984.158">Overly WL, Dankoff JA, Wang BK, Singh ND. Androgens and hepatocellular carcinoma in an athlete. <span><span class="ref-journal">Ann Intern Med. </span>1984;<span class="ref-vol">100</span>:158–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6318626" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6318626</span></a>]<div>
|
|
<i>(26 year old on multiple anabolic steroids for body building for 4 years developed weakness and weight loss and found to have hepatocellular carcinoma).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.lyon.1984.647">Lyon J, Bookstein JL, Cartwright CA, Romano A, Heeney DJ. Peliosis hepatis: diagnosis by magnification wedged hepatic venography. <span><span class="ref-journal">Radiology. </span>1984;<span class="ref-vol">150</span>:647–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6695062" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6695062</span></a>]<div>
|
|
<i>(29 year old man with aplastic anemia on oxymetholone for 4 years developed abdominal pain [bilirubin 1.7 mg/dL, ALT 1000 U/L, Alk P 188 U/L], venogram showing changes of peliosis and liver biopsy showing diffuse peliosis and hemorrhage and small adenomas).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.mays.1984.147">Mays ET, Christopherson W. Hepatic tumors induced by sex steroids. <span><span class="ref-journal">Semin Liver Dis. </span>1984;<span class="ref-vol">4</span>:147–57.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6087460" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6087460</span></a>]<div>
|
|
<i>(Review of experience with 201 benign tumors of liver in women, ages 14 to 57; 98 focal nodular hyperplasia, 2 adenoma and 23 hepatocellular carcinoma, 9 unclassified; oral contraceptive use in 82% regardless of type).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.pelletier.1984.269">Pelletier G, Frija J, Szekely AM, Clauvel JP. Adenoma of the liver in man. <span><span class="ref-journal">Gastroenterol Clin Biol. </span>1984;<span class="ref-vol">8</span>:269–72.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6325285" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6325285</span></a>]<div>
|
|
<i>(26 year old man with solitary hepatic adenoma; review of literature found only 31 cases of adenomas in men, 8 of whom had received anabolic steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.zafrani.1984.349">Zafrani ES, Casier A, Baudelot A-M, Feldmann G. Ultrastructural lesions of the liver in human peliosis: a report of 12 cases. <span><span class="ref-journal">Am J Pathol. </span>1984;<span class="ref-vol">114</span>:349–59.</span> [<a href="/pmc/articles/PMC1900425/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1900425</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6696047" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6696047</span></a>]<div>
|
|
<i>(Electron microscopy of liver biopsies from 12 patients with peliosis, 5 with jaundice, 4 with portal hypertension, ALT elevated in 6, Alk P in 9 and bilirubin in 7: dilation of sinusoids and space of Disse; one case attributed to anabolic steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.goldman.1985.56">Goldman B. Liver carcinoma in an athlete taking anabolic steroids. <span><span class="ref-journal">J Am Osteopath Assoc. </span>1985;<span class="ref-vol">85</span>:56.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2984149" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2984149</span></a>]<div>
|
|
<i>(37 year old male athlete taking oxymetholone for 5 years developed 4 pound “malignant tumor”).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.mccaughan.1985.2622">McCaughan GW, Bilous MJ, Gallagher ND. Long-term survival with tumor regression in androgen-induced liver tumors. <span><span class="ref-journal">Cancer. </span>1985;<span class="ref-vol">56</span>:2622–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2996742" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2996742</span></a>]<div>
|
|
<i>(Two patients with hepatocellular carcinoma arising after 5 and 6 years of therapy with oxymetholone and methyltestosterone had tumor regression on stopping anabolic steroids and survival for more than 10 years).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.lowdell.1985.637">Lowdell CP, Murray-Lyon IM. Reversal of liver damage due to long term methyltestosterone and safety of non-17 alpha-alkylated androgens. <span><span class="ref-journal">Br Med J (Clin Res Ed). </span>1985;<span class="ref-vol">291</span>:637.</span> [<a href="/pmc/articles/PMC1417521/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1417521</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3928062" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3928062</span></a>]<div>
|
|
<i>(1 to 6 year follow up of 42 patients with liver injury from methyltestosterone [Westaby 1977]; all recovered and those on sublingual testosterone had normal liver tests and liver scans).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.nuzzo.1985.518">Nuzzo JL, Manz HJ, Maxted WC. Peliosis hepatis after long-term androgen therapy. <span><span class="ref-journal">Urology. </span>1985;<span class="ref-vol">25</span>:518–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3992778" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3992778</span></a>]<div>
|
|
<i>(After 13 years of testosterone and 16 months of fluoxymesterone replacement therapy, patient presented with jaundice that resolved on reducing dose; on autopsy 5 years later, liver histology showed peliosis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.buamah.1985.114">Buamah PK. An apparent danazol induced primary hepatocellular carcinoma. <span><span class="ref-journal">J Surg Oncol. </span>1985;<span class="ref-vol">28</span>:114–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2578590" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2578590</span></a>]<div>
|
|
<i>(49 year old woman treated with danazol for 2 years for endometriosis presented with jaundice and pain, laparotomy showing hepatocellular carcinoma in noncirrhotic liver).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.carrasco.1985.573">Carrasco D, Prieto M, Pallardo L, Moll JL, Cruz JM, Monoz C, Berenguer J. Multiple hepatic adenomas after long-term therapy with testosterone enanthate. <span><span class="ref-journal">J Hepatol. </span>1985;<span class="ref-vol">1</span>:573–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2997324" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2997324</span></a>]<div>
|
|
<i>(32 year old man with renal transplant treated with testosterone enanthate for 12 years developed hepatic masses found to be adenomas).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.nesher.1985.242">Nesher G, Dolberg L, Zimran A, Hershko A. Hepatosplenic peliosis after danazol and glucocorticoids for ITP. <span><span class="ref-journal">N Engl J Med. </span>1985;<span class="ref-vol">312</span>:242–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4038421" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4038421</span></a>]<div>
|
|
<i>(74 year old woman with immune thrombocytopenia treated with danazol for 3 months was found to have peliosis hepatis during splenectomy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.nordsten.1985.2615">Nordsten M. <span><span class="ref-journal">Ugeskr Laeger. </span>1985;<span class="ref-vol">147</span>:2615–6.</span> [Hemangiosarcoma of the liver associated with administration of androgenic steroids] Danish. [<a href="https://pubmed.ncbi.nlm.nih.gov/4071695" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4071695</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.garrigues_gil.1986.135">Garrigues Gil V, Berenguer Lapuerta J, Ponce García J, Rayón Martín M. A non-C17 alkylated steroid and long-term cholestasis. <span><span class="ref-journal">Ann Intern Med. </span>1986;<span class="ref-vol">104</span>:135–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3940497" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3940497</span></a>]<div>
|
|
<i>(27 year old woman developed jaundice 4 months after starting 19-norandrostenolone with prolonged jaundice [bilirubin 10.8 m/dL, ALT 310 U/L, Alk P 1560 U/L], lasting 14 months and complete resolution at 21 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.serke.1986.111">Serke S, Dienemann D, Speck B, Zimmermann R, Baer U, Huhn D. Hepatocellular carcinoma and focal nodular hyperplasia associated with norethandrolone-therapy: a case report. <span><span class="ref-journal">Blut. </span>1986;<span class="ref-vol">52</span>:111–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3004620" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3004620</span></a>]<div>
|
|
<i>(33 year old woman with aplastic anemia treated with norethandrolone for 4 years presented with abdominal pain and hepatic masses, one being focal nodular hyperplasia and one hepatocellular carcinoma; no follow up given).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kir_ly.1988.249">Király CL. Androgen-anabolic steroid effects on serum and skin surface lipids, on red cells, and on liver enzymes. <span><span class="ref-journal">Int J Sports Med. </span>1988;<span class="ref-vol">9</span>:249–52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2972634" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2972634</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.boue.1986.139">Boue F, Coffin B, Delfraissy JF. Danazol and cholestatic hepatitis. <span><span class="ref-journal">Ann Intern Med. </span>1986;<span class="ref-vol">105</span>:139–40.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3717792" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3717792</span></a>]<div>
|
|
<i>(73 year old woman with thrombocytopenic purpura developed pruritus and abnormal liver tests 4 weeks after starting danazol but without jaundice [ALT 57 U/L, peak Alk P 619 U/L], pruritus persisted for 3 weeks, liver test abnormalities for 3 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.lucey.1987.461">Lucey MR, Moseley RH. Severe cholestasis associated with methyltestosterone: a case report. <span><span class="ref-journal">Am J Gastroenterol. </span>1987;<span class="ref-vol">82</span>:461–2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3578226" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3578226</span></a>]<div>
|
|
<i>(62 year old man developed fatigue followed by jaundice 8 months after starting methyltestosterone [bilirubin 29 mg/dL, AST 243 I/L, Alk P 290 U/L], resolving within 2 months of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.ishak.1987.230">Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. <span><span class="ref-journal">Semin Liver Dis. </span>1987;<span class="ref-vol">7</span>:230–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3317860" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3317860</span></a>]<div>
|
|
<i>(Thorough review of the hepatic complications of androgenic steroid use, including cholestasis, peliosis, hyperplastic nodules, nodular regeneration, adenomas, hepatocellular carcinoma and other hepatic malignancies).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.evely.1987.612">Evely RS, Triger DR, Milnes JP, Low-Beer TS, Williams R. Severe cholestasis associated with stanozolol. <span><span class="ref-journal">Br Med J (Clin Res Ed). </span>1987;<span class="ref-vol">294</span>:612–3.</span> [<a href="/pmc/articles/PMC1245653/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1245653</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3103828" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3103828</span></a>]<div>
|
|
<i>(Three patients, ages 62 to 65 years, developed jaundice and pruritus 1-5 months after starting stanozolol [bilirubin 38.6-46.7 mg/dL, AST 56-69 U/L, Alk P 284-732 U/L], resolving 3-6 months after drug withdrawal).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.oda.1987.29">Oda K, Oguma N, Kawano M, Kimura A, Kuramoto A, Tokumo K. Hepatocellular carcinoma associated with long-term anabolic steroid therapy in two patients with aplastic anemia. <span><span class="ref-journal">Nippon Ketsueki Gakkai Zasshi. </span>1987;<span class="ref-vol">50</span>:29–36.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3035855" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3035855</span></a>]<div>
|
|
<i>(Two patients with aplastic anemia treated with oxymetholone for 12-15 years developed multiple liver tumors and had hepatocellular carcinoma without cirrhosis on autopsy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kir_ly.1988.249_1">Király CL. Androgenic-anabolic steroid effects on serum and skin surface lipids, on red cells, and on liver enzymes. <span><span class="ref-journal">Int J Sports Med. </span>1988;<span class="ref-vol">9</span>:249–52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2972634" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2972634</span></a>]<div>
|
|
<i>(Prospective study of 7 power athletes taking multiple anabolic steroids during 6 weeks of training; ALT levels rose [~28 to 52 U/L] and HDL cholesterol levels decreased).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.creagh.1988.441">Creagh TM, Rubin A, Evans DJ. Hepatic tumors induced by anabolic steroids in an athlete. <span><span class="ref-journal">J Clin Pathol. </span>1988;<span class="ref-vol">41</span>:441–3.</span> [<a href="/pmc/articles/PMC1141472/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1141472</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2835401" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2835401</span></a>]<div>
|
|
<i>(27 year old male body builder on anabolic steroids for 3 years presented with rupture of large hepatocellular carcinoma).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.lenders.1988.19">Lenders JW, Demacker PN, Vos JA, Jansen AJ, Hoitsma AJ. van ‘t Laar, Thien T. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, liver function in amateur body builders. <span><span class="ref-journal">Int J Sports Med. </span>1988;<span class="ref-vol">9</span>:19–23.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3366514" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3366514</span></a>]<div>
|
|
<i>(Among 58 body builders, ALT and AST levels were higher among those currently on anabolic steroids [mean ALT=57 U/L] compared to previous users [36 U/L] and never users [19 U/L], and levels rose during a course of anabolic steroids [29 to 67 U/L]).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.veneri.1988.467">Veneri RJ, Gordon SC. Anabolic steroid-induced cholestasis: choleretic response to corticosteroids. <span><span class="ref-journal">J Clin Gastroenterol. </span>1988;<span class="ref-vol">10</span>:467–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3418094" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3418094</span></a>]<div>
|
|
<i>(29 year old male body builder with a history of pruritus and jaundice after starting anabolic steroids developed prolonged pruritus and jaundice 4 months after a one month course of testosterone enanthate injections [bilirubin 16.4 mg/dL, ALT 47 U/L, Alk P 205 U/L], with apparent response to prednisone therapy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.middleton.1989.733">Middleton C, McCaughan GW, Painter DM, Stephen MS, Beale M, Fraser I. Danazol and hepatic neoplasia: a case report. <span><span class="ref-journal">Aust N Z J Med. </span>1989;<span class="ref-vol">19</span>:733–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2561047" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2561047</span></a>]<div>
|
|
<i>(35 year old woman presented with a large hepatocellular carcinoma after several years of intermittent danazol therapy for endometriosis with improvement on stopping danazol and resection).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.winwood.1990.864">Winwood PJ, Robertson DA, Wright R. Bleeding oesophageal varices associated with anabolic steroid use in an athlete. <span><span class="ref-journal">Postgrad Med J. </span>1990;<span class="ref-vol">66</span>:864–5.</span> [<a href="/pmc/articles/PMC2429716/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2429716</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2099434" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2099434</span></a>]<div>
|
|
<i>(30 year old male body builder on anabolic steroids for 18 months developed variceal hemorrhage; liver biopsy was read as normal and varices were no longer detected after steroids were stopped).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.gleeson.1991.1084">Gleeson D, Newbould MJ, Taylor P, McMahon RF, Leahy BC, Warnes TW. Androgen associated hepatocellular carcinoma with an aggressive course. <span><span class="ref-journal">Gut. </span>1991;<span class="ref-vol">32</span>:1084–6.</span> [<a href="/pmc/articles/PMC1379057/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1379057</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1655591" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1655591</span></a>]<div>
|
|
<i>(48 year old man on methyltestosterone for primary hypogonadism for 24 years presented with abdominal pain and hepatocellular carcinoma; withdrawal of androgens led to regression, but 2 years later he had progressive metastatic disease and died; he was also anti-HCV positive).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kuipers.1991.413">Kuipers H, Wijnen J, Hartgen F, Willems S. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver function in body builders. <span><span class="ref-journal">Int J Sports Med. </span>1991;<span class="ref-vol">12</span>:413–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1917227" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1917227</span></a>]<div>
|
|
<i>(Prospective study of testosterone vs nandrolone vs placebo intramuscular injections for 8 weeks in 50 male and female body builders; androgens led to increase in muscle mass, but also a 25% decrease in HDL cholesterol and increase in diastolic blood pressure; but “all enzyme values remained within the normal range”).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.s_e.1992.73">Søe KL, Søe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. <span><span class="ref-journal">Liver. </span>1992;<span class="ref-vol">12</span>:73–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1535676" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1535676</span></a>]<div>
|
|
<i>(Review of adverse effects of anabolic steroids on the liver with a focus on histologic changes).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.touraine.1993.691">Touraine RL, Bertrand Y, Foray P, Gilly J, Philippe N. Hepatic tumours during androgen therapy in Fanconi anaemia. <span><span class="ref-journal">Eur J Pediatr. </span>1993;<span class="ref-vol">152</span>:691–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8404976" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8404976</span></a>]<div>
|
|
<i>(12 year old boy with Fanconi’s anemia developed jaundice after 4.5 years of norethandrolone therapy with three hepatic masses, 4, 8 and 12 cm in size and diagnosed as hepatic adenomas; there was partial resolution on stopping androgen therapy as shown by 50% shrinkage after 16 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.cabasso.1994.2">Cabasso A. Peliosis hepatis in a young adult bodybuilder. <span><span class="ref-journal">Med Sci Sports Exerc. </span>1994;<span class="ref-vol">26</span>:2–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8133732" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8133732</span></a>]<div>
|
|
<i>(27 year old male body builder taking various anabolic steroids for 8 years presented with abdominal pain and hepatic mass compatible with peliosis by CT scan, which regressed on stopping androgens).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.gurakar.1994.399">Gurakar A, Caraceni P, Fagiuoli S, Van Thiel DH. Androgenic/anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports. <span><span class="ref-journal">J Okla State Med Assoc. </span>1994;<span class="ref-vol">87</span>:399–404.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7996313" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7996313</span></a>]<div>
|
|
<i>(4 cases of jaundice due to anabolic steroid use; all men, ages 63, 33, 53 and 26 years, taking anabolic steroids [methyltestosterone, stanozolol or oral testosterone], for 1-5 months, developed jaundice [bilirubin 13.2, 44.3, 47.8, and 19.5 mg/dL, ALT 52, 12, 27 and 33 U/L, Alk P 337, 189, 294, and 137 U/L], with slow resolution 5-12 months after stopping androgens).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.wood.1994.201">Wood P, Yin JA. Oxymetholone hepatotoxicity enhanced by concomitant use of cyclosporin A in a bone marrow transplant patient. <span><span class="ref-journal">Clin Lab Haematol. </span>1994;<span class="ref-vol">16</span>:201–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7955931" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7955931</span></a>]<div>
|
|
<i>(16 year old boy with acute leukemia and bone marrow transplant developed jaundice 2 months after starting oxymetholone [bilirubin 4.0 mg/dL, ALT 488 U/L, Alk P 442 U/L], abnormalities persisting for 3 months after stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.yoshida.1994.791">Yoshida EM, Karim MA, Shaikh JF, Soos JG, Erb SR. At what price, glory? Severe cholestasis and acute renal failure in an athlete abusing stanozolol. <span><span class="ref-journal">CMAJ. </span>1994;<span class="ref-vol">151</span>:791–3.</span> [<a href="/pmc/articles/PMC1337134/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1337134</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8087755" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8087755</span></a>]<div>
|
|
<i>(26 year old male power lifter developed jaundice one month after starting stanozolol [bilirubin 19.6 rising to 51.2 mg/dL, AST 33 U/L, Alk P 137 U/L], complicated by acute renal failure, biopsy showing intrahepatic cholestasis, resolving slowly over the following 5 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bhasin.1996.1">Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. <span><span class="ref-journal">N Engl J Med. </span>1996;<span class="ref-vol">335</span>:1–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8637535" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8637535</span></a>]<div>
|
|
<i>(Controlled trial of testosterone enanthate vs placebo for 10 weeks in 43 normal men who were also randomized to exercise or not; testosterone increased muscle size and strength; no change in liver enzymes).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.singh.1996.783">Singh C, Bishop P, Wilson R. Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements and ethanol: response to ursodeoxycholic acid treatment. <span><span class="ref-journal">Am J Gastroenterol. </span>1996;<span class="ref-vol">91</span>:783–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8677950" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8677950</span></a>]<div>
|
|
<i>(24 year old male body builder developed jaundice after 3 month use of several anabolic steroids [stanozolol and nandrolone] and Ma Huang [bilirubin 21 rising to 53 mg/dL, ALT 237 U/L, Alk P 129 U/L], with prolonged jaundice and pruritus resolving 5 months after onset: Case 1).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.staub.1996.172">Staub PG, Leibowitz CB. Peliosis hepatis associated with oral contraceptive use. <span><span class="ref-journal">Australas Radiol. </span>1996;<span class="ref-vol">40</span>:172–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8687355" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8687355</span></a>]<div>
|
|
<i>(35 year old woman on oral contraceptives for several years developed abdominal pain and abnormal imaging studies with multiple lesions of varying size [2-5 cm], biopsy showing peliosis with decrease in size of lesions 6 months after stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kosaka.1996.450">Kosaka A, Takahashi H, Yajima Y, Tanaka M, Okamura K, Mizumoto R, Katsuta K. Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. <span><span class="ref-journal">J Gastroenterol. </span>1996;<span class="ref-vol">31</span>:450–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8726841" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8726841</span></a>]<div>
|
|
<i>(35 year old woman with aplastic anemia developed hepatocellular carcinoma 3 years after starting oxymetholone therapy, with long term survival after resection and stopping androgens; review of 12 cases reported from Japan).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.m_rk.1997.1087">Mörk H, al-Taie O, Klinge O, Scheurlen M. <span><span class="ref-journal">Z Gastroenterol. </span>1997;<span class="ref-vol">35</span>:1087–91.</span> [Successful therapy of persistent androgen-induced cholestasis with ursodeoxycholic acid] German. [<a href="https://pubmed.ncbi.nlm.nih.gov/9487641" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9487641</span></a>]<div>
|
|
<i>(55 year old man developed jaundice 12 months after starting methyltestosterone [bilirubin 5.1 mg/dL, ALT 177 U/L, Alk P normal]; when bilirubin rose to 8.0 mg/dL, ursodiol was started with resolution in 3 months, whereupon ursodiol was stopped without recurrence).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.dourakis.1998.7">Dourakis SP, Tolis G. Sex hormonal preparations and the liver. <span><span class="ref-journal">Eur J Contracept Reprod Health Care. </span>1998;<span class="ref-vol">3</span>:7–16.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9678067" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9678067</span></a>]<div>
|
|
<i>(Review of sex hormones and liver injury; for estrogens complications include cholestasis, cholelithiasis, Budd-Chiari syndrome, peliosis, adenomas and focal nodular hyperplasia and hepatocellular carcinoma; androgenic steroids are not discussed).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.schumacher.1999.1123">Schumacher J, Muller G, Klotz K-F. Large hepatic hematoma and intraabdominal hemorrhage associated with abuse of anabolic steroids. <span><span class="ref-journal">N Engl J Med. </span>1999;<span class="ref-vol">340</span>:1123–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10206841" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10206841</span></a>]<div>
|
|
<i>(24 year old male body builder developed hepatic hemorrhage and rupture having used anabolic steroids for 2 years [bilirubin normal, ALT 927 U/L, Alk P normal], biopsy showing extensive hepatic necrosis without malignancy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.habscheid.1999.1029">Habscheid W, Abele U, Dahm HH. <span><span class="ref-journal">Dtsch Med Wochenschr. </span>1999;<span class="ref-vol">124</span>:1029–32.</span> [Severe cholestasis with kidney failure from anabolic steroids in a body builder] German. [<a href="https://pubmed.ncbi.nlm.nih.gov/10506840" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10506840</span></a>]<div>
|
|
<i>(28 year old male body builder developed jaundice 3 months after starting anabolic steroids [initial bilirubin 4.5 mg/dL, ALT 38 U/L, Alk P 94 U/L], with worsening jaundice and renal failure despite stopping androgens [peak bilirubin 77.9 mg/dL], jaundice lasting 4 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bork.1999.1066">Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. <span><span class="ref-journal">Lancet. </span>1999;<span class="ref-vol">353</span>:1066–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10199359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10199359</span></a>]<div>
|
|
<i>(Among 87 patients with hereditary angioneurotic edema, 41 were treated with danazol, 11 for more than 10 years, 3 of whom developed hepatocellular adenomas at ages 29, 39 and 67 which were resected and did not show carcinoma).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bagia.2000.686">Bagia S, Hewitt PM, Morris DL. Anabolic steroid-induced hepatic adenomas with spontaneous haemorrhage in a bodybuilder. <span><span class="ref-journal">Aust N Z J Surg. </span>2000;<span class="ref-vol">70</span>:686–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10976903" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10976903</span></a>]<div>
|
|
<i>(31 year old male body builder on long term anabolic steroids presented with hemorrhage into a hepatic adenoma ultimately requiring resection).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.simon.2001.281">Simon JA. Safety of estrogen/androgen regimens. <span><span class="ref-journal">J Reprod Med. </span>2001;<span class="ref-vol">46</span>(3) Suppl:281–90.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11304876" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11304876</span></a>]<div>
|
|
<i>(Combinations of estrogen with low doses of methyltestosterone [1.25-2.5 mg] have been used to treat vasomotor symptoms in menopausal women with no serious adverse events, including no hepatic events or liver-enzyme elevations, in 641 women followed prospectively in controlled trials).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.stimac.2002.350">Stimac D, Milić S, Dintinjana RD, Kovac D, Ristić S. Androgenic/Anabolic steroid-induced toxic hepatitis. <span><span class="ref-journal">J Clin Gastroenterol. </span>2002;<span class="ref-vol">35</span>:350–2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12352300" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12352300</span></a>]<div>
|
|
<i>(26 year old male body builder developed nausea and jaundice 5 weeks after starting anabolic steroids [bilirubin 27.5 mg/dL, ALT 10,580 U/L, Alk P 152 U/L] which he had taken intermittently for 9 years; gradual improvement over 3 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.hengge.2003.699">Hengge UR, Stocks K, Wiehler H, Faulkner S, Esser S, Lorenz C, Jentzen W, et al. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. <span><span class="ref-journal">AIDS. </span>2003;<span class="ref-vol">17</span>:699–710.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12646793" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12646793</span></a>]<div>
|
|
<i>(Controlled trial of 16 weeks of oxymetholone vs placebo is 89 HIV-infected patients; ALT levels rose above 5 times ULN in 31% of oxymetholone, but none of placebo treated patients; one developed jaundice and cholestasis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.tan.2004.599">Tan RS, Salazar JA. Risks of testosterone replacement therapy in ageing men. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2004;<span class="ref-vol">3</span>:599–606.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15500418" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15500418</span></a>]<div>
|
|
<i>(Review of use of androgens in aging males for loss of libido and inability to focus mentally; “to our knowledge, there has been no reported hepatotoxicity from testosterone delivered via topical gel, transdermal patch, or by intramuscular injections”).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.orr.2004.725">Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. <span><span class="ref-journal">Drugs. </span>2004;<span class="ref-vol">64</span>:725–50.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15025546" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15025546</span></a>]<div>
|
|
<i>(Review of clinical efficacy and side effects of anabolic steroids and oxandrolone which is approved for use to promote weight gain and decrease catabolism after surgery or severe trauma).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.hartgens.2004.513">Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. <span><span class="ref-journal">Sports Med. </span>2004;<span class="ref-vol">34</span>:513–54.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15248788" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15248788</span></a>]<div>
|
|
<i>(Review of effects and toxicity of anabolic steroids used to improve athletic performance; “Injectable testosterone cypionate and enanthate preparations do not appear to affect liver function enzymes”).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.velazquez.2004.257">Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. <span><span class="ref-journal">Am J Hematol. </span>2004;<span class="ref-vol">77</span>:257–67.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15495253" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15495253</span></a>]<div>
|
|
<i>(Systematic review of published literature on association of androgen therapy and liver tumors identified 133 cases, 36 in patients with Fanconi’s anemia, others with aplastic anemia, endocrine and gynecological disorders and body builders; most due to oxymetholone, methyltestosterone and danazol, but 6 associated with intramuscular testosterone injections; hepatocellular carcinoma 53%, adenomas 37%, others included cholangiocarcinoma and angiosarcoma).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.maravelias.2005.167">Maravelias C, Dona A, Stefanidou M, Spiliopoulou C. Adverse effects of anabolic steroids in athletes. A constant threat. <span><span class="ref-journal">Toxicol Lett. </span>2005;<span class="ref-vol">158</span>:167–75.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16005168" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16005168</span></a>]<div>
|
|
<i>(Review of adverse effects of anabolic steroids in athletes; hepatic effects include serum enzyme elevations, cholestatic jaundice, hepatic tumors and peliosis hepatis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.socas.2005.e27">Socas L, Zumbado M, Pérez-Luzardo O, Ramos A, Pérez C, Hernández J R, Boada L D. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. <span><span class="ref-journal">Br J Sports Med. </span>2005;<span class="ref-vol">39</span>:e27. </span> [<a href="/pmc/articles/PMC1725213/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1725213</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15849280" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15849280</span></a>]<div>
|
|
<i>(Two cases of hepatic adenomas in male body builders abusing anabolic steroids; ages 35 and 23 years old on anabolic steroids for 6 months and 15 years presented with hepatic masses which appeared to be benign and regressed on stopping anabolic steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.capra.2005.1535">Capra F, Nicolini N, Morana G, Guglielmi A, Capelli P, Vantini I. Vanishing bile duct syndrome and inflammatory pseudotumor associated with a case of anabolic steroid abuse. <span><span class="ref-journal">Dig Dis Sci. </span>2005;<span class="ref-vol">50</span>:1535–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16110850" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16110850</span></a>]<div>
|
|
<i>(32 year old treated for 3 years with testosterone undecanoate for hypogonadism developed jaundice [bilirubin 37 mg/dL, ALT 182 U/L, Alk P 212 U/L], with inflammatory pseudo tumor and biopsy showing paucity of bile ducts, although patient ultimately recovered).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.clark.2005.756">Clark BM, Schofield RS. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. <span><span class="ref-journal">Pharmacotherapy. </span>2005;<span class="ref-vol">25</span>:756–61.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15899737" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15899737</span></a>]<div>
|
|
<i>(40 year old man developed shortness of breath and jaundice starting 2 months after initiating therapy with androgens and ephedra to promote muscle development [bilirubin 3.9 mg/dL, ALT 2173 U/L, Alk P normal], requiring therapy for congestive cardiomyopathy, but ultimately recovering over next 18 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.jasiurkowski.2006.2659">Jasiurkowski B, Raj J, Wisinger D, Carlson R, Zou L, Nadir A. Cholestatic jaundice and IgA nephropathy induced by OTC muscle building agent Superdrol. <span><span class="ref-journal">Am J Gastroenterol. </span>2006;<span class="ref-vol">101</span>:2659–62.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16952289" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16952289</span></a>]<div>
|
|
<i>(23 year old body builder developed abdominal pain and jaundice two months after starting an over-the-counter supplement called “Superdrol” [containing methasteron] [bilirubin 36.2 mg/dL, ALT 93 U/L, Alk P 224 U/L], with protracted jaundice and itching and biopsy showing marked cholestasis with minimal inflammation).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kafrouni.2007.809">Kafrouni MI, Anders RA, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2007;<span class="ref-vol">5</span>:809–12.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17509944" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17509944</span></a>]<div>
|
|
<i>(Two cases; 31 and 40 year old body builders developed prolonged jaundice and pruritus beginning 4 and 6 weeks after starting “Superdrol” [bilirubin 37.5 and 49.7 mg/dL, ALT 59 and 301 U/L, Alk P 375 and 416 U/L], with slow recovery over ensuing 2-3 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.mccullough.2007.412">McCullough MC, Namias N, Schulman C, Gomez E, Manning R, Goldberg S, Pizano L, et al. Incidence of hepatic dysfunction is equivalent in burn patients receiving oxandrolone and controls. <span><span class="ref-journal">J Burn Care Res. </span>2007;<span class="ref-vol">28</span>:412–20.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17438485" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17438485</span></a>]<div>
|
|
<i>(Retrospective analysis of liver test results during oxandrolone therapy of patients with major burns; some evidence of hepatic dysfunction found in 43% of oxandrolone and 43% of 61 control subjects).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.patil.2007.462">Patil JJ, O'Donohoe B, Loyden CF, Shanahan D. Near-fatal spontaneous hepatic rupture associated with anabolic androgenic steroid use: a case report. <span><span class="ref-journal">Br J Sports Med. </span>2007;<span class="ref-vol">41</span>:462–3.</span> [<a href="/pmc/articles/PMC2465371/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2465371</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17224443" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17224443</span></a>]<div>
|
|
<i>(43 year old professional body builder developed abdominal pain and hepatic rupture having used anabolic steroids for 25 years; cause of rupture not explained [peliosis vs adenoma vs carcinoma]).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, et al. Drug Induced Liver Injury Network(DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18955056" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div>
|
|
<i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, at least 6 were due to anabolic steroids being used for body building or for improving athletic performance, but none were attributed to physician-prescribed androgenic steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.s_nchezosorio.2008.278">Sánchez-Osorio M, Duarte-Rojo A, Martínez-Benítez B, Torre A, Uribe M. Anabolic-androgenic steroids and liver injury. <span><span class="ref-journal">Liver Int. </span>2008;<span class="ref-vol">28</span>:278–82.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17900246" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17900246</span></a>]<div>
|
|
<i>(29 year old man developed progressive fatigue, nausea and then jaundice and pruritis 2-3 months after starting high dose anabolic steroids [bilirubin 29 mg/dL, ALT 54 U/L, Alk P 694 U/L], jaundice persisting for 2 months, but resolving completely by 5 months after stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.gorayski.2008.74">Gorayski P, Thompson CH, Subhash HS, Thomas AC. Hepatocellular carcinoma associated with recreational anabolic steroid use. <span><span class="ref-journal">Br J Sports Med. </span>2008;<span class="ref-vol">42</span>:74–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18178686" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18178686</span></a>]<div>
|
|
<i>(35 year old male body builder presented with large hepatocellular carcinoma having used anabolic steroids for several years [bilirubin 0.6 mg/dL, ALT 364 U/L, Alk P 70 U/L, alpha-fetoprotein normal], no follow up provided).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.martin.2008.4573">Martin NM, Abu Dayyeh BK, Chung RT. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. <span><span class="ref-journal">World J Gastroenterol. </span>2008;<span class="ref-vol">14</span>:4573–5.</span> [<a href="/pmc/articles/PMC2731289/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2731289</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18680242" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18680242</span></a>]<div>
|
|
<i>(27 year old male body builder having used anabolic steroids for 5 years had spontaneous hepatic bleeding from 10 cm hepatic adenoma [bilirubin 2.2 mg/dL, ALT 2457 U/L, Alk P 275 U/L], treated with resection and had recurrence 3 years later having restarted anabolic steroid use).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.shah.2008.255">Shah NL, Zacharias I, Khettry U, Afdhal N, Gordon FD. Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2008;<span class="ref-vol">6</span>:255–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18187367" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18187367</span></a>]<div>
|
|
<i>(5 cases of jaundice due to methasteron use by male body builders, ages 20 to 33 years, with onset of symptoms 1-2 months after starting the nutritional supplement [initial bilirubin 7.6-41.8 mg/dL, ALT 59-151 U/L, Alk P 85-189 U/L], all resolving with stopping the 17-alkylated androgenic steroid).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.singh.2009.287">Singh V, Rudraraju M, Carey EJ, Byrne TJ, Vargas HE, Williams JE, Balan V, et al. Severe hepatotoxicity caused by a methasteron-containing performance-enhancing supplement. <span><span class="ref-journal">J Clin Gastroenterol. </span>2009;<span class="ref-vol">43</span>:287.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18813027" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18813027</span></a>]<div>
|
|
<i>(3 men, ages 25, 33, and 51, developed jaundice and pruritus 1-2 months after starting "Superdrol", a form of methasteron [bilirubin 8.3, 17.3 and 22 mg/dL, ALT 69, 236 and 1025 U/L, Alk P 106, 111 and unknown U/L] associated with hepatic encephalopathy and peak INR 1.5, in one patient, but resolving spontaneously in all within 6-12 weeks of onset).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.nasr.2009.1144">Nasr J, Ahmad J. Severe cholestasis and renal failure associated with the use of the designer steroid Superdrol (methasteron): a case report and literature review. <span><span class="ref-journal">Dig Dis Sci. </span>2009;<span class="ref-vol">54</span>:1144–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18720005" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18720005</span></a>]<div>
|
|
<i>(42 year old man developed jaundice and pruritus 7 weeks after starting "Superdrol" with methasteron [bilirubin 41.2 mg/dL, ALT 98 U/L, Alk P 353 U/L, creatinine 3.5 mg/dL], both renal and liver injury resolving slowly over the following 4 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.choi.2009.5493">Choi SK, Jin JS, Cho SG, Choi SJ, Kim CS, Choe YM, Lee KY. Spontaneous liver rupture in a patient with peliosis hepatis: a case report. <span><span class="ref-journal">World J Gastroenterol. </span>2009;<span class="ref-vol">15</span>:5493–7.</span> [<a href="/pmc/articles/PMC2778108/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2778108</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19916182" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19916182</span></a>]<div>
|
|
<i>(20 year old man with aplastic anemia treated with oxymetholone for 8 years developed spontaneous rupture of liver due to peliosis hepatis, responding to hemi-hepatectomy and stopping androgenic steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bispo.2009.2920">Bispo M, Valente A, Maldonado R, Palma R, Glória H, Nóbrega J, Alexandrino P. Anabolic steroid-induced cardiomyopathy underlying acute liver failure in a young bodybuilder. <span><span class="ref-journal">World J Gastroenterol. </span>2009;<span class="ref-vol">15</span>:2920–2.</span> [<a href="/pmc/articles/PMC2699014/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2699014</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19533818" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19533818</span></a>]<div>
|
|
<i>(40 year old body builder developed fatigue followed by jaundice having used large doses of anabolic steroids for 10 years [bilirubin 6.8 mg/dL, ALT 7125 U/L, INR 3.3, LDH 7140 U/L], acute liver failure being due to ischemic hepatitis caused by cardiomyopathy, responding rapidly to treatment of right heart failure).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.masumori.2009.530">Masumori N, Ikeda H, Endo T. Acute hepatitis induced by replacement oral testosterone product in a female-to-male patient with gender identity disorder. <span><span class="ref-journal">Int J Urol. </span>2009 May;<span class="ref-vol">16</span>(5):530–1.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19467123" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19467123</span></a>]<div>
|
|
<i>(27 year old female-to-male transgender woman developed fatigue 3 months after switching from fluoxymesterone to methyltestosterone [both oral 17-alpha methylated androgenic steroids] [bilirubin 1.2 mg/dL, peak ALT 1418 U/L, Alk P not given], resolving within 6 weeks of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.krishnan.2009.672">Krishnan PV, Feng ZZ, Gordon SC. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements. <span><span class="ref-journal">J Clin Gastroenterol. </span>2009;<span class="ref-vol">43</span>:672–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19238093" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19238093</span></a>]<div>
|
|
<i>(Three cases of anabolic steroid induced hepatotoxicity; 21, 30 and 38 year old men developed jaundice and pruritus 4 to 8 weeks after starting a nutritional supplement with an oral anabolic steroid [bilirubin 8.0-53 mg/dL, ALT 200-467 U/L, Alk P 104-494 U/L], with slow recovery after stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20949552" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div>
|
|
<i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were linked to anabolic steroid use).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.woerdeman.2010.a2004">Woerdeman J, de Hon O, Levi M, de Ronde WP. <span><span class="ref-journal">Ned Tijdschr Geneeskd. </span>2010;<span class="ref-vol">154</span>:A2004.</span> [Anabolic androgenic steroids in amateur sports in the Netherlands] Dutch. [<a href="https://pubmed.ncbi.nlm.nih.gov/20858322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20858322</span></a>]<div>
|
|
<i>(Review of anabolic steroid use in the Netherlands and their complications including cholestasis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.wingert.2010.340">Wingert N, Tavakoli H, Yoder E. Acute hepatitis and personality change in a 31-year-old man taking prohormone supplement SUS500. <span><span class="ref-journal">Psychosomatics. </span>2010;<span class="ref-vol">51</span>:340–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20587764" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20587764</span></a>]<div>
|
|
<i>(31 year man developed fatigue and personality change having used an prohormone nutritional supplement for one year [ALT 1754 U/L, bilirubin and Alk P not given], resolving rapidly after stopping the supplement).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.van_amsterdam.2010.117">van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. <span><span class="ref-journal">Regul Toxicol Pharmacol. </span>2010;<span class="ref-vol">57</span>:117–23.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20153798" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20153798</span></a>]<div>
|
|
<i>(Review of the health consequences of anabolic steroid use including cholestasis, hepatic adenoma and peliosis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.b_ttner.2010.459">Büttner A, Thieme D. Side effects of anabolic androgenic steroids: pathological findings and structure-activity relationships. <span><span class="ref-journal">Handb Exp Pharmacol. </span>2010;(195):459–84.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20020376" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20020376</span></a>]<div>
|
|
<i>(Review of the side effects of anabolic steroids based upon structure-activity relationships).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.tornai.2010.1132">Tornai I. <span><span class="ref-journal">Orv Hetil. </span>2010;<span class="ref-vol">151</span>:1132–6.</span> [Role of environmental factors in the etiology of hepatocellular carcinoma] [<a href="https://pubmed.ncbi.nlm.nih.gov/20570793" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20570793</span></a>]<div>
|
|
<i>(Review of risk factors for hepatocellular carcinoma mentions that oral contraceptives may play a role in some cases).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.schwingel.2011.348">Schwingel PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, Andrade AR, et al. Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease. <span><span class="ref-journal">Liver Int. </span>2011;<span class="ref-vol">31</span>:348–53.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21040407" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21040407</span></a>]<div>
|
|
<i>(Among 180 recreational body builders, mean aminotransferase levels were higher [ALT: 43 vs 31 U/L and AST: 55 vs 32 U/L] and more likely to be elevated [33% vs 7%] in those who admitted to use of injectable anabolic steroids, who were also more likely to have steatosis by ultrasound evaluation).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.machado.2011.280">Machado MV, Cortez-Pinto H. The dark side of sports: using steroids may harm your liver. <span><span class="ref-journal">Liver Int. </span>2011;<span class="ref-vol">31</span>:280–1.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21281427" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21281427</span></a>]<div>
|
|
<i>(Editorial in response to Schwingel [2011]).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.yurci.2011.845">Yurci A, Yucesoy M, Unluhizarci K, Torun E, Gursoy S, Baskol M, Guven K, Ozbakir O. Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis. <span><span class="ref-journal">Clin Res Hepatol Gastroenterol. </span>2011;<span class="ref-vol">35</span>:845–54.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22074639" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22074639</span></a>]<div>
|
|
<i>(Among 10 hypogonadal men with cirrhosis treated with transdermal testosterone, there was no change in ALT or bilirubin and none developed clinically apparent liver injury).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.rosenfeld.2011.138">Rosenfeld GA, Chang A, Poulin M, Kwan P, Yoshida E. Cholestatic jaundice, acute kidney injury and acute pancreatitis secondary to the recreational use of methandrostenolone: a case report. <span><span class="ref-journal">J Med Case Rep. </span>2011;<span class="ref-vol">5</span>:138.</span> [<a href="/pmc/articles/PMC3079674/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3079674</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21470406" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21470406</span></a>]<div>
|
|
<i>(50 year old man with chronic hepatitis C developed anorexia, weight loss and jaundice 8 weeks after starting methandrostenolone [bilirubin 53.9 mg/dL, ALT 56 U/L, Alk P 154 U/L] accompanied by mild pancreatitis and renal insufficiency, resolving slowly after stopping anabolic steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.neri.2011.430">Neri M, Bello S, Bonsignore A, Cantatore S, Riezzo I, Turillazzi E, Fineschi V. Anabolic androgenic steroids abuse and liver toxicity. <span><span class="ref-journal">Mini Rev Med Chem. </span>2011;<span class="ref-vol">11</span>:430–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21443508" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21443508</span></a>]<div>
|
|
<i>(Review of the hepatic complications of anabolic steroid use).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.stickel.2011.595">Stickel F, Kessebohm K, Weimann R, Seitz HK. Review of liver injury associated with dietary supplements. <span><span class="ref-journal">Liver Int. </span>2011;<span class="ref-vol">31</span>:595–605.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21457433" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21457433</span></a>]<div>
|
|
<i>(Review of current understanding of liver injury from herbals and dietary supplements focusing upon herbalife and hydroxycut products, green tea, usnic acid, Noni juice, Chinese herbs, vitamin A and anabolic steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.avelarescobar.2012.564">Avelar-Escobar G, Méndez-Navarro J, Ortiz-Olvera NX, Castellanos G, Ramos R, Gallardo-Cabrera VE, Vargas-Alemán Jde J, et al. Hepatotoxicity associated with dietary energy supplements: use and abuse by young athletes. <span><span class="ref-journal">Ann Hepatol. </span>2012;<span class="ref-vol">11</span>:564–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22700641" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22700641</span></a>]<div>
|
|
<i>(17 year old boy developed jaundice and pruritus 3 months after starting dietary supplements [N.O.Xplode, Growth Factor ATN and SimiCaritina] for body building [bilirubin 17.5 rising to 31.5 mg/dL, ALT 640 U/L, Alk P 850 U/L, GGT normal], with resolution within 6-8 weeks of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kou.2012.e11">Kou T, Watanabe M, Yazumi S. Hepatic failure during anabolic steroid therapy. <span><span class="ref-journal">Gastroenterology. </span>2012;<span class="ref-vol">143</span>:e11–2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23085354" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23085354</span></a>]<div>
|
|
<i>(78 year old man developed jaundice and fatigue 2 years after starting danazol for thrombocytopenic purpura [bilirubin 11.7 mg/dL, ALT 185 U/L, Alk P 677 U/L] and died 26 days later, autopsy showing peliosis hepatis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.timchehhariri.2012.3826">Timcheh-Hariri A, Balali-Mood M, Aryan E, Sadeghi M, Riahi-Zanjani B. Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. <span><span class="ref-journal">Food Chem Toxicol. </span>2012;<span class="ref-vol">50</span>:3826–32.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22809474" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22809474</span></a>]<div>
|
|
<i>(20 male body builders, ages 24 to 32 years, presented with jaundice and pruritus having been taking 3 supplements for a year [bilirubin 3.9-8.0 mg/dL, ALT 225-600 U/L, Alk P 325-701 U/L], the responsible agent causing the injury being unclear from the list of ingredients).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.elsharkawy.2012.e468">Elsharkawy AM, McPherson S, Masson S, Burt AD, Dawson RT, Hudson M. Cholestasis secondary to anabolic steroid use in young men. <span><span class="ref-journal">BMJ. </span>2012;<span class="ref-vol">344</span>:e468. </span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22302781" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22302781</span></a>]<div>
|
|
<i>(Two cases, 16 and 32 year old men developed jaundice and pruritus 5 days and 2 months after starting an anabolic steroid "methandrostenolone" [bilirubin 25.8 and 38.0 mg/dL, ALT 156 and 76 U/L, Alk P 203 and 262 U/L], requiring 4 months to resolve after stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.elsharkawy.2012">Elsharkawy AM, McPherson S, Masson S, Burt A, Dawson RT, Hudson M. [Cholestasis in young men after taking anabolic steroids]. Praxis (Bern 1994) 2012; 101: 661-4. German. [<a href="https://pubmed.ncbi.nlm.nih.gov/22565557" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22565557</span></a>]<div><i>(Same cases as described by the authors in BMJ [2012]).</i></div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.porro.2012.489">Porro LJ, Herndon DN, Rodriguez NA, Jennings K, Klein GL, Mlcak RP, Meyer WJ, et al. Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy. <span><span class="ref-journal">J Am Coll Surg. </span>2012;<span class="ref-vol">214</span>:489–502.</span> [<a href="/pmc/articles/PMC3412530/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3412530</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22463890" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22463890</span></a>]<div>
|
|
<i>(Among children with severe burns, 70 received oxandrolone for one year and 152 served as standard of care controls; ALT levels were elevated to a similar degree in both groups during the acute period, returning to normal levels 3-6 months after the burns).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.paiscosta.2012.180">Pais-Costa SR, Lima OA, Soares AF. Giant hepatic adenoma associated with anabolic-androgenic steroid abuse: case report. <span><span class="ref-journal">Arq Bras Cir Dig. </span>2012;<span class="ref-vol">25</span>:180–2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23411809" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23411809</span></a>]<div>
|
|
<i>(28 year old male body builder developed abdominal pain having been on anabolic steroids for 6 years, surgery revealing two hepatic adenomas, one being 10 cm in diameter).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.vilella.2013.e33">Vilella AL, Limsuwat C, Williams DR, Seifert CF. Cholestatic jaundice as a result of combination designer supplement ingestion. <span><span class="ref-journal">Ann Pharmacother. </span>2013;<span class="ref-vol">47</span>:e33. </span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23757384" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23757384</span></a>]<div>
|
|
<i>(50 year old man developed jaundice and pruritus 2 months after starting body building supplements [bilirubin 29.4 mg/dL, ALT 125 U/L, Alk P 160 U/L], with slow recovery upon stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.el_sherrif.2013.1266">El Sherrif Y, Potts JR, Howard MR, Barnardo A, Cairns S, Knisely AS, Verma S. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? <span><span class="ref-journal">Liver Int. </span>2013;<span class="ref-vol">33</span>:1266–70.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23750872" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23750872</span></a>]<div>
|
|
<i>(Two men, ages 25 and 45 years, developed jaundice 3 and 6 weeks after starting an anabolic steroid "Mass-Drol" [bilirubin 10.8 and 6.0 mg/dL, ALT 207 and 152 U/L, Alk P 137 and 259 U/L, GGT 72 and 59 U/L = normal], sequencing of ABC B11 [the gene that is abnormal in FIC1] was normal).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.hymel.2013.133">Hymel BM, Victor DW, Alvarez L, Shores NJ, Balart LA. Mastabol induced acute cholestasis: A case report. <span><span class="ref-journal">World J Hepatol. </span>2013;<span class="ref-vol">5</span>:133–6.</span> [<a href="/pmc/articles/PMC3612572/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3612572</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23556046" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23556046</span></a>]<div>
|
|
<i>(26 year old man developed jaundice and pruritus 10 days after starting daily injections of the anabolic steroid "Mastabol" [peak bilirubin 23.6 mg/dL, ALT 117 U/L, Alk P 441 U/L], improving slowly on withdrawal).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.archer.2013.147">Archer JR, Dargan PI, Hudson S, Wood DM. Analysis of anonymous pooled urine from portable urinals in central London confirms the significant use of novel psychoactive substances. <span><span class="ref-journal">QJM. </span>2013;<span class="ref-vol">106</span>:147–52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23178933" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23178933</span></a>]<div>
|
|
<i>(Analysis of pooled urine samples collected from 12 public urinals in central London identified cocaine, cannabis and MDMA from 11 sites, amphetamines from 10 and anabolic steroids from 4).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bj_rnsson.2013.1419">Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23419359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div>
|
|
<i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, including 15 due to herbals and dietary supplements, including one each attributed to Dianabol [methandrostenolone], "Mega men heart" and "Serious Mass").</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.supasyndh.2013.271">Supasyndh O, Satirapoj B, Aramwit P, Viroonudomphol D, Chaiprasert A, Thanachatwej V, Vanichakarn S, et al. Effect of oral anabolic steroid on muscle strength and muscle growth in hemodialysis patients. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2013;<span class="ref-vol">8</span>:271–9.</span> [<a href="/pmc/articles/PMC3562853/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3562853</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23124786" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23124786</span></a>]<div>
|
|
<i>(Among 43 hemodialysis patients treated with oxymetholone or placebo for 24 weeks, fat free mass and handgrip strength increased with the androgenic steroid, but liver enzymes rose from a mean serum ALT of 15 to 70 U/L and direct bilirubin from 0.09 to 0.51 mg/dL and one patient stopped therapy early because of “cholestatic hepatitis”).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.hoedebecke.2013.1">Hoedebecke K, Rerucha C, Maxwell K, Butler J. Drug-induced liver injury secondary to testosterone prohormone dietary supplement use. <span><span class="ref-journal">J Spec Oper Med. </span>2013;<span class="ref-vol">13</span>:1–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24227554" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24227554</span></a>]<div>
|
|
<i>(28 year old Special Services member developed pruritus and jaundice 4 weeks after starting a testosterone prohormone supplement [bilirubin 13.6 mg/dL rising to 27.2 ten days later, ALT 693 U/L, Alk P not given], with slow recovery).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.ding.2013.215">Ding NS, De Cruz P, Lim L, Thompson A, Desmond P. Androgenic-anabolic steroid drug-induced liver injury. <span><span class="ref-journal">Intern Med J. </span>2013;<span class="ref-vol">43</span>:215–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23402488" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23402488</span></a>]<div>
|
|
<i>(46 year old man took two anabolic steroids for two months and developed jaundice several months later [bilirubin 17.8 mg/dL, ALT 125 U/L, Alk P 295 U/L, GGT 114 U/L], resolving on no therapy within 7 weeks).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bauman.2013.718">Bauman WA, Spungen AM, Collins JF, Raisch DW, Ho C, Deitrick GA, Nemchausky BA, et al. The effect of oxandrolone on the healing of chronic pressure ulcers in persons with spinal cord injury: a randomized trial. <span><span class="ref-journal">Ann Intern Med. </span>2013;<span class="ref-vol">158</span>:718–26.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23689765" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23689765</span></a>]<div>
|
|
<i>(Among 41 patients with pressure ulcers treated with oxandrolone or placebo for 24 weeks, ulcer healing was not affected but asymptomatic ALT elevations arose in 32% on androgenic steroids vs 2.9% on placebo, and 4.6% of patients stopped therapy early because of liver test abnormalities, all of which resolved within 4 weeks of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.luciano.2014.473">Luciano RL, Castano E, Moeckel G, Perazella MA. Bile acid nephropathy in a bodybuilder abusing an anabolic androgenic steroid. <span><span class="ref-journal">Am J Kidney Dis. </span>2014;<span class="ref-vol">64</span>:473–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24953892" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24953892</span></a>]<div>
|
|
<i>(41 year old man developed weight loss, pruritus and jaundice 6 weeks after starting nandrolone twice weekly, testosterone once weekly and daily methandrostenolone [bilirubin 11.8 rising to 47.9 mg/dL, ALT 267 U/L, Alk P 162 U/L], with worsening renal function [creatinine rising to 2.9 mg/dL] but ultimate full recovery).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.awai.2014.e32">Awai HI, Yu EL, Ellis LS, Schwimmer JB. Liver toxicity of anabolic androgenic steroid use in an adolescent with nonalcoholic fatty liver disease. <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>2014;<span class="ref-vol">59</span>:e32–3.</span> [<a href="/pmc/articles/PMC3772995/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3772995</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23568051" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23568051</span></a>]<div>
|
|
<i>(18 year old male with history of NASH developed jaundice 2 weeks after starting “Beastrdrol” [bilirubin 11 rising to 28 mg/dL, ALT 229 U/L, GGT 65 U/L], resolving within 3 months of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.hern_ndez.2014.231">Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24552865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div>
|
|
<i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, only one was attributed to an androgenic steroid [nandrolone]).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div>
|
|
<i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 185 were attributed to HDS but only 31 [3.5%] to anabolic steroids).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.abbate.2015.609">Abbate V, Kicman AT, Evans-Brown M, McVeigh J, Cowan DA, Wilson C, Coles SJ, et al. Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health. <span><span class="ref-journal">Drug Test Anal. </span>2015;<span class="ref-vol">7</span>(7):609–18.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25284752" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25284752</span></a>]<div>
|
|
<i>(24 products sold at fitness store were analyzed and 23 were found to have anabolic steroids, with 16 different than package label and one without steroids. Of 13 different anabolic steroids identified, 12 were controlled substance emphasizing the availability of anabolic steroids in herbal supplements).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.roblesdiaz.2015.116">Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, Stephens C, García-Cortes M, García-Muñoz B, Ortega-Alonso A, et al. Spanish DILI Registry; SLatinDILI Network. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. <span><span class="ref-journal">Aliment Pharmacol Ther. </span>2015;<span class="ref-vol">41</span>:116–25.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25394890" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25394890</span></a>]<div>
|
|
<i>(Combination of Spanish and Latin American databases included 25 cases of anabolic steroid jaundice [8% of cases from 2010-2013], all men, mean age 32 [bilirubin 12 times, ALT 14 times, and Alk P 1.3 times ULN], renal dysfunction developing in 6 [24%] all with bilirubin levels above 35 mg/dL, but ultimate recovery in all and no mortality).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.schwingel.2015.1490">Schwingel PA, Cotrim HP, Santos CR Jr, Santos AO, Andrade AR, Carruego MV, Zoppi CC. Recreational anabolic-androgenic steroid use associated with liver injuries among Brazilian young men. <span><span class="ref-journal">Subst Use Misuse. </span>2015;<span class="ref-vol">50</span>:1490–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26549387" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26549387</span></a>]<div>
|
|
<i>(Among 923 Brazilian recreational body builders, 182 [20%] admitted to anabolic steroid use [long term but often intermittent], of whom 38.5% had elevated liver enzymes and 12% had hepatic steatosis by ultrasound; one had focal nodular hyperplasia and one a hepatic adenoma but none evidently had jaundice or clinically apparent liver injury).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.brazeau.2015.e844">Brazeau MJ, Castaneda JL, Huitron SS, Wang J. A case report of supplement-induced hepatitis in an active duty service member. <span><span class="ref-journal">Mil Med. </span>2015;<span class="ref-vol">180</span>:e844–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26126259" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26126259</span></a>]<div>
|
|
<i>(26 year old Army soldier developed jaundice 4 months after starting “Mutant Plexx” for body building being unaware that it contained anabolic steroids [bilirubin 4.9 mg/dL, ALT 223 U/L], resolving within 3 months of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.tabatabaee.2015.331">Tabatabaee SM, Elahi R, Savaj S. Bile cast nephropathy due to cholestatic jaundice after using stanozolol in 2 amateur bodybuilders. <span><span class="ref-journal">Iran J Kidney Dis. </span>2015;<span class="ref-vol">9</span>:331–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26174462" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26174462</span></a>]<div>
|
|
<i>(Two men, ages 30 and 43 years, developed jaundice and renal dysfunction 3 and 6 weeks after starting oral and parenteral stanozolol [bilirubin 48 and 49 mg/dL, ALT 33 and 66 U/L, Alk P 535 and 690 U/L, creatinine 8.7 and 1.9 mg/dL], both ultimately requiring dialysis but eventually recovering).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.flores.2016.133">Flores A, Nustas R, Nguyen HL, Rahimi RS. Severe cholestasis and bile acid nephropathy from anabolic steroids successfully treated with plasmapheresis. <span><span class="ref-journal">ACG Case Rep J. </span>2016;<span class="ref-vol">3</span>:133–5.</span> [<a href="/pmc/articles/PMC4748206/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4748206</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26958570" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26958570</span></a>]<div>
|
|
<i>(31 year old man developed jaundice 16 weeks after starting a regimen that included 2 anabolic steroids [bilirubin 53 mg/dL] with severe pruritus, weight loss, hepatic encephalopathy and renal dysfunction treated with plasmapheresis with subsequent improvement).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bourgeois.2016.14">Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, Bagheri H. Risk of hormonotherapy in transgender people: Literature review and data from the French Database of Pharmacovigilance. <span><span class="ref-journal">Ann Endocrinol (Paris). </span>2016;<span class="ref-vol">77</span>:14–21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26830952" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26830952</span></a>]<div>
|
|
<i>(Review of the literature and adverse event registries on medical regimens for transgender individuals, trans-males receiving antiestrogens [GnRH analogues and antigonadotropins] and testosterone, which can be associated with serum enzyme elevations but has not been linked to clinically apparent liver injury).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.alkhunaizi.2016.121">Alkhunaizi AM, ElTigani MA, Rabah RS, Nasr SH. Acute bile nephropathy secondary to anabolic steroids. <span><span class="ref-journal">Clin Nephrol. </span>2016;<span class="ref-vol">85</span>:121–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26587777" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26587777</span></a>]<div>
|
|
<i>(28 year old man developed jaundice 6 months after starting a body building regimen that included several anabolic steroids [bilirubin 5.6 rising to 44 mg/dL, ALT and Alk P not provided], with accompanying bilirubin nephropathy and bile stained urinary granular casts and renal tubular epithelial cells).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.bond.2016.150">Bond P, Llewellyn W, Van Mol P. Anabolic androgenic steroid-induced hepatotoxicity. <span><span class="ref-journal">Med Hypotheses. </span>2016;<span class="ref-vol">93</span>:150–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27372877" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27372877</span></a>]<div>
|
|
<i>(Hypothesis suggesting that potent engagement of the androgen receptor by synthetic anabolic steroids would up-regulate carnitine palmitoyltransferase 1 [CPT1], which controls mitochondrial fatty acid β-oxidation and would result in generation of reactive oxygen species that would damage hepatocytes).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.magee.2016.e1169">Magee CD, Witte S, Kwok RM, Deuster PA. Mission compromised? drug-induced liver injury from prohormone supplements containing anabolic-androgenic steroids in two deployed U.S. service members. <span><span class="ref-journal">Mil Med. </span>2016;<span class="ref-vol">181</span>:e1169–71.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27612377" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27612377</span></a>]<div>
|
|
<i>(Two actively deployed service members developed liver injury 3-4 weeks after starting combinations of products said to be prohormone supplements [one with jaundice and one with serum ALT elevations], and testing of the products [“TANK”, “DMZ” and “Epi-10”] revealed several anabolic steroids including stanozolol, methyltestosterone and methasteron among others).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.cabb.2016.499">Cabb E, Baltar S, Powers DW, Mohan K, Martinez A, Pitts E. The diagnosis and manifestations of liver injury secondary to off-label androgenic anabolic steroid use. <span><span class="ref-journal">Case Rep Gastroenterol. </span>2016;<span class="ref-vol">10</span>:499–505.</span> [<a href="/pmc/articles/PMC5043289/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5043289</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27721739" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27721739</span></a>]<div>
|
|
<i>(45 year old man developed jaundice and pruritus 3 months after starting two anabolic steroids [bilirubin 4.9 rising to 6.4 mg/dL, ALT 102 U/L, Alk P 262 U/L], resolving in follow up).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.boks.2017.2262">Boks MN, Tiebosch AT, van der Waaij LA. A jaundiced bodybuilder; cholestatic hepatitis as side effect of injectable anabolic-androgenic steroids. <span><span class="ref-journal">J Sports Sci. </span>2017;<span class="ref-vol">35</span>:2262–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27937337" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27937337</span></a>]<div>
|
|
<i>(24 year old man developed pruritus and jaundice several weeks after finishing an 8 week cycle of trenbolone enanthate, a C-19 and C-17β substituted androgenic steroid used in cattle and used by body builders under the popular name “Tren”, [bilirubin 9.3 rising to 31.5 mg/dL, ALT 115 U/L, Alk P 70 U/L, GGT 36 U/L], worsening for 6 weeks but ultimately resolving).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.solimini.2017.7">Solimini R, Rotolo MC, Mastrobattista L, Mortali C, Minutillo A, Pichini S, Pacifici R, et al. Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping. <span><span class="ref-journal">Eur Rev Med Pharmacol Sci. </span>2017;<span class="ref-vol">21</span>(1) Suppl:7–16.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28379599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28379599</span></a>]<div>
|
|
<i>(Review of the mechanism of action of androgenic steroids and their synthetic derivatives, usually with either 17-α alkylation, which creates an orally available, anabolic product that is capable of causing cholestasis, or 17-β esterification that creates an hydrophobic and long acting form of testosterone and is not likely to cause cholestasis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.velho.2017.881">Velho I, Fighera TM, Ziegelmann PK, Spritzer PM. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. <span><span class="ref-journal">Andrology. </span>2017;<span class="ref-vol">5</span>:881–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28709177" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28709177</span></a>]</div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.eapen.2018.omx077">Eapen J, Ayoola R, Subramanian RM. 'The efficacy of extracorporeal liver support with molecular adsorbent recirculating system in severe drug-induced liver injury'. <span><span class="ref-journal">Oxf Med Case Reports. </span>2018;<span class="ref-vol">2018</span>:omx077. </span> [<a href="/pmc/articles/PMC5751031/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5751031</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29308212" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29308212</span></a>]<div>
|
|
<i>(Systematic review of the literature on studies of adverse effects of testosterone [parenteral undecanoate, cypionate, enanthate, propionate or topical gel or patch] therapy for transgender men identified six studies that included tests of liver function which changed minimally or not at all, no levels rising above the upper limits of normal for men).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.medinacaliz.2018.1495">Medina-Caliz I, Garcia-Cortes M, Gonzalez-Jimenez A, Cabello MR, Robles-Diaz M, Sanabria-Cabrera J, Sanjuan-Jimenez R, et al. Spanish DILI Registry. Herbal and dietary supplement-induced liver injuries in the Spanish DILI Registry. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2018;<span class="ref-vol">16</span>:1495–502.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29307848" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29307848</span></a>]<div>
|
|
<i>(Among 856 cases of drug induced liver injury enrolled in a Spanish registry between 1994 and 2016, 32 [3.7%] were due to HDS products and another 20 [2.3%] to anabolic steroids; only in men, mean age 31 years, 95% with jaundice, none fatal, and mean bilirubin 17 times, ALT 14 times, GGT 1.8 times and Alk P 1.3 times ULN).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.hassan.2018.357">Hassan A, Fontana RJ. Liver injury associated with sporting activities. <span><span class="ref-journal">Semin Liver Dis. </span>2018;<span class="ref-vol">38</span>:357–65.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30357773" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30357773</span></a>]<div>
|
|
<i>(Review of liver injury associated with athletic activities discusses heat stroke, anabolic steroid jaundice and HDS induced liver injury from body building supplements).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.kiracofe.2019.891">Kiracofe B, Coffey R, Jones LM, Bailey JK, Thomas S, Porter K, Murphy CV. Incidence of oxandrolone induced hepatic transaminitis in patients with burn injury. <span><span class="ref-journal">Burns. </span>2019;<span class="ref-vol">45</span>:891–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30545697" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30545697</span></a>]<div>
|
|
<i>(Among 66 patients hospitalized for significant body burns treated with oxandrolone with frequent monitoring, 28 [42%] developed elevations in ALT or AST, but abnormalities were asymptomatic and transient and there was no mention of clinically apparent liver injury).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.stolz.2019.1195">Stolz A, Navarro V, Hayashi PH, Fontana RJ, Barnhart HX, Gu J, Chalasani NP, et al. DILIN Investigators. Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. <span><span class="ref-journal">Aliment Pharmacol Ther. </span>2019;<span class="ref-vol">49</span>:1195–204.</span> [<a href="/pmc/articles/PMC6682544/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6682544</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30934130" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30934130</span></a>]<div>
|
|
<i>(Among 44 patients with anabolic steroid jaundice enrolled in a prospective database between 2004 and 2013, all were men, aged 21 to 59 years presenting with jaundice an average of 2.5 months after starting the steroid [bilirubin 9.8 rising to 25.8 mg/dL, ALT 169 U/L, Alk P 111 U/L], jaundice persisting for an average of 3 months, but ultimately resolving with no mortality or liver transplantation; various rare and function affecting variants in the bile acid transporter genes were found but none consistently).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.zheng.2020.141">Zheng E, Sandhu N, Navarro V. Drug-induced liver injury secondary to herbal and dietary supplements. <span><span class="ref-journal">Clin Liver Dis. </span>2020;<span class="ref-vol">24</span>:141–55.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31753247" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31753247</span></a>]<div>
|
|
<i>(Review of HDS associated liver injury including that caused by anabolic steroids which has increase in the last 2 decades both in US and European registries, the typical case marked by intense and prolonged cholestasis arising 1-4 months after starting an anabolic steroid, rarely fatal, liver histology showing marked canalicular cholestasis with minimal inflammation and necrosis, referred to as bland cholestasis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.petrov.2020.589">Petrov PD, Fernández-Murga L, Conde I, Martínez-Sena T, Guzmán C, Castell JV, Jover R. Epistane, an anabolic steroid used for recreational purposes, causes cholestasis with elevated levels of cholic acid conjugates, by upregulating bile acid synthesis (CYP8B1) and cross-talking with nuclear receptors in human hepatocytes. <span><span class="ref-journal">Arch Toxicol. </span>2020;<span class="ref-vol">94</span>:589–607.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31894354" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31894354</span></a>]<div>
|
|
<i>(Among 3 patients with bland cholestasis due to epistane, all had marked increases in serum bile acids, largely primary conjugated forms; while in vitro studies demonstrated that epistane increases bile acid synthesis in hepatocytes, with no change in SHP and decrease in FGF-19 with accompanying increases in bile acid synthetic genes and increases in transporters; epistane also activates the androgen receptor and increases bile acid levels via CYP8B1).</i>
|
|
</div></div></li><li><div class="bk_ref" id="AndrogenicSteroids.REF.flores.2020.450">Flores JE, Chitturi S, Walker S. Drug-induced liver injury by selective androgenic receptor modulators. <span><span class="ref-journal">Hepatol Commun. </span>2020;<span class="ref-vol">4</span>:450–2.</span> [<a href="/pmc/articles/PMC7049679/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7049679</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32140660" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32140660</span></a>]<div>
|
|
<i>(Two patients, 24 and 49 year old men, developed jaundice 10 weeks and 4 months after starting over-the-counter selective androgen receptor modulators [SARMs] called Ligandrol and RAD-140 for body building [bilirubin 6.8 and 17.1 mg/dL, ALT 273 and 54 U/L, Alk P 289 and 327 U/L], resolving in follow up at 4 and 12 months after stopping the products).</i>
|
|
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548931_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">May 30, 2020</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Androgenic Steroids. [Updated 2020 May 30].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Anastrozole/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/GeneralAnesthetics/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobAndrogenicSteroidsTc"><div id="AndrogenicSteroids.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548931/table/AndrogenicSteroids.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__AndrogenicSteroids.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_AndrogenicSteroids.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_AndrogenicSteroids.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anabolic steroids (nandrolone, stanozolol)</td></tr><tr><th id="hd_b_AndrogenicSteroids.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_AndrogenicSteroids.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bland cholestasis</td></tr><tr><th id="hd_b_AndrogenicSteroids.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_AndrogenicSteroids.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3+ (jaundice, hospitalization)</td></tr><tr><th id="hd_b_AndrogenicSteroids.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Latency:</th><td headers="hd_b_AndrogenicSteroids.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 months</td></tr><tr><th id="hd_b_AndrogenicSteroids.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_AndrogenicSteroids.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.6 months</td></tr><tr><th id="hd_b_AndrogenicSteroids.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_AndrogenicSteroids.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Various herbal products and dietary supplements</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobAndrogenicSteroidsTd"><div id="AndrogenicSteroids.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548931/table/AndrogenicSteroids.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__AndrogenicSteroids.Td_lrgtbl__"><table><thead><tr><th id="hd_h_AndrogenicSteroids.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_AndrogenicSteroids.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ALT<br />(U/L)</th><th id="hd_h_AndrogenicSteroids.Td_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_AndrogenicSteroids.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Bilirubin<br />(mg/L)</th><th id="hd_h_AndrogenicSteroids.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_1 hd_h_AndrogenicSteroids.Td_1_1_1_2 hd_h_AndrogenicSteroids.Td_1_1_1_3 hd_h_AndrogenicSteroids.Td_1_1_1_4 hd_h_AndrogenicSteroids.Td_1_1_1_5" colspan="6" scope="col" rowspan="1" style="text-align:center;vertical-align:top;">Anabolic agent use for ~1.5 years</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">129</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3 hd_h_AndrogenicSteroids.Td_1_1_1_4" colspan="2" rowspan="1" style="text-align:center;vertical-align:top;">21</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 weeks</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">90</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">121</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3 hd_h_AndrogenicSteroids.Td_1_1_1_4" colspan="2" rowspan="1" style="text-align:center;vertical-align:top;">53</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 weeks</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">203</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">91</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3 hd_h_AndrogenicSteroids.Td_1_1_1_4" colspan="2" rowspan="1" style="text-align:center;vertical-align:top;">51</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Ursodiol started</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 weeks</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">119</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">81</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3 hd_h_AndrogenicSteroids.Td_1_1_1_4" colspan="2" rowspan="1" style="text-align:center;vertical-align:top;">22</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 weeks</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">116</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">67</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3 hd_h_AndrogenicSteroids.Td_1_1_1_4" colspan="2" rowspan="1" style="text-align:center;vertical-align:top;">8</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 months</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">58</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">50</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3 hd_h_AndrogenicSteroids.Td_1_1_1_4" colspan="2" rowspan="1" style="text-align:center;vertical-align:top;">4</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 months</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">33</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">75</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3 hd_h_AndrogenicSteroids.Td_1_1_1_4" colspan="2" rowspan="1" style="text-align:center;vertical-align:top;">1.5</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Asymptomatic</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Normal Values</b>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><56</b>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><139</b>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_3 hd_h_AndrogenicSteroids.Td_1_1_1_4" colspan="2" rowspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><1.2</b>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobAndrogenicSteroidsTe"><div id="AndrogenicSteroids.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548931/table/AndrogenicSteroids.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__AndrogenicSteroids.Te_lrgtbl__"><table><thead><tr><th id="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_AndrogenicSteroids.Te_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY<br />NUMBER</th><th id="hd_h_AndrogenicSteroids.Te_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR<br />FORMULA</th><th id="hd_h_AndrogenicSteroids.Te_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Danazol</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134993037" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">17230-88-5</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C22-H27-N-O2</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134993037" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134993037" alt="image 134993037 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Fluoxymesterone</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971676" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">76-43-7</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C20-H29-F-O3</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971676" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134971676" alt="image 134971676 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methandienone</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134972636" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">72-63-9</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C20-H28-O2</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134972636" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134972636" alt="image 134972636 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methenolone</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134973444" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">303-42-4</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C27-H42-O3</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134973444" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134973444" alt="image 134973444 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methyltestosterone</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971513" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">58-18-4</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C20-H30-O2</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971513" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134971513" alt="image 134971513 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nandrolone</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134973631" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">360-70-3</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C28-H44-O3</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134973631" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134973631" alt="image 134973631 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Norethandrolone</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970693" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">52-78-8</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C20-H30-O2</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970693" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134970693" alt="image 134970693 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oxandrolone</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971185" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">53-39-4</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C19-H30-O3</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971185" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134971185" alt="image 134971185 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oxymetholone</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134974328" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">434-07-1</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C21-H32-O3</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134974328" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134974328" alt="image 134974328 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stanozolol</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134991118" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">10418-03-8</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C21-H32-N2-O</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134991118" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134991118" alt="image 134991118 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Testosterone</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971515" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">58-20-8</a>
|
|
</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C27-H40-O3</td><td headers="hd_h_AndrogenicSteroids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971515" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134971515" alt="image 134971515 in the ncbi pubchem database" /></a>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|